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Nucleic acid amplification tests (NAATs) are widely implemented as infectious 
disease diagnostics due to their high sensitivity and specificity. Polymerase chain 
reaction (PCR) tests are the most commonly diagnostic NAAT. PCR requires the 
use of equipment for temperature cycling and instrumentation to monitor reaction 
progress and often require upstream sample preparation to isolate nucleic acids 
from a raw clinical samples. As such, PCR-based tests are most commonly used 
large and well-resourced healthcare systems where clinical samples are 
collected from patients and transported to a centralized testing laboratory. 
Point-of-care diagnostic testing (POCT) is a complementary paradigm to 
centralized testing where testing infrastructure and consumables are 
disseminated throughout a healthcare system such that diagnostic testing can be 
performed on-site with the patient nearby. POCT methods enable test-and-treat 
strategies commonly implemented in STI screening programs and obviate issues 
associated with patient loss to follow up. When developing NAATs for POCT, it is 




especially in low resourced settings where access to laboratory resources may 
be limited. Recently, isothermal NAA methods, which eliminate the need for 
costly thermocycling equipment, have garnered use in POCT applications often 
coupled with visual readout methods to eliminate instrumentation requirements. 
In this work, I expand upon these existing isothermal NAA methods to develop 
POCT with both qualitative and semiquantitative detection capabilities. First, I 
developed a thermophilic helicase dependent amplification (tHDA) assay for the 
detection of the STI Trichomonas vaginalis (TV) and a competitive internal 
control. This assay is compatible with visual readout via a low cost lateral flow 
immunoassay (LFIA) device. I also developed a simple yet effective strategy for 
rapid nucleic acid extraction and enrichment from urine. When coupled, the 
sample preparation strategy and tHDA assay were able to detect TV at a 
concentration of 0.25 TV genomes per mL. I observed 96.6% sensitivity and 
100% specificity when testing clinical urine samples. Second, I developed a 
novel test for semiquantitative detection of hepatitis B virus (HBV) DNA at two 
tunable thresholds with LFIA readout. Chronic HBV patients require serial viral 
load monitoring to inform initiation of antiretroviral therapy (ART) and ensure 
continued treatment efficacy for patients receiving ART. I demonstrated the 
tunability of the semiquantitative ligation and amplification assay by controllably 
setting two independent quantification thresholds to specific HBV viral load 
concentrations used in chronic HBV case management. This assay can be 
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Introduction and Thesis Overview 
1.1 Nucleic acid amplification testing for infectious diseases in central 
clinical laboratories and at the point-of-care 
The original nucleic acid amplification testing (NAAT) technique, polymerase 
chain reaction (PCR), was first reported by Mullis et al. in 19861, and for the first 
time enabled the specific, exponential amplification of dilute DNA sequences to 
detectible levels. Advances in PCR technology evolved rapidly. The discovery of 
reverse transcriptase in 1970 laid the ground work for reverse transcriptase PCR 
(RT-PCR), which enabled detection of RNA sequences2. In 1986, utilization of a 
thermostable DNA polymerase derived from Thermus aquaticus able to 
withstand the high temperatures required for PCR greatly simplified workflow of 
the PCR technique3. In 1992, incorporation of ethidium bromide into the PCR 
reaction mixture enabled continuous monitoring of the PCR process via 
fluorescent signal generation, paving the way for quantitative PCR (qPCR)4. 
Over the past three decades, NAATs, including PCR-based tests, have 
emerged as the preeminent method for the detection and diagnosis of infectious 
disease and have garnered wide use in clinical laboratories5. Traditionally, 
healthcare systems have implemented a paradigm of centralized clinical 
laboratory testing where samples are collected from patients and sent to a 




provider. This paradigm offers many clear advantages. Laboratory equipment, 
clinical testing instrumentation, and trained personnel can operate in a single 
location in the centralized testing model. In this set up, many samples, collected 
from across a given healthcare system, can be prepared and tested in highly 
parallel processes thereby reducing overhead and improving throughput. Thus, in 
healthcare systems with high testing volume and adequate resources, the 
(typically) high principal and operating costs of sophisticated clinical testing 
instrumentation is easily justified by savings achieved on a per test basis through 
scaling. Further, use of a centralized laboratory model simplifies reporting and 
record keeping processes required to maintain patient records appropriately. 
However, the centralized testing model does have noteworthy drawbacks. In 
some healthcare systems, implementation of a centralized testing model can 
introduce undesirable delays in sample-to-answer time, especially in instances 
where timely diagnoses are known to improve outcomes. These delays may 
arise due to geographical and logistical constraints encountered during sample 
transportation from the collection site to the central laboratory. Importantly, 
delays in sample-to-answer time can also arise due to challenges related to 
communicating a test result from the central to the relevant healthcare provider 
and patient. These challenges are potentiated in rural, remote, and low-
resourced settings. Further, for healthcare systems with low testing volume and 
inadequate resources, the principal and operational costs associated with 




can prove untenable. 
Recognizing the potential drawbacks of a pure centralized clinical laboratory 
model, point-of-care testing (POCT) has gained ground in recent years as a 
complementary diagnostic testing paradigm6. In the POCT model, diagnostic 
equipment and consumables are disseminated throughout or strategically 
deployed within a healthcare system to enable on-site sample collection and 
testing thereby reducing sample-to-answer time. In some use cases, POCT can 
enable so called test-and-treat intervention strategies enabling single visit 
management of certain infections.  
Of course, the POCT paradigm has its drawbacks as well. High redundancy in 
diagnostic equipment is an intrinsic feature of the POCT model; this is acceptable 
in some instances where equipment costs are relatively low (e.g. glucometers for 
individuals with diabetes), but problematic when equipment costs are high. By 
extension, in many use cases, POCT methods must be able to perform without 
typical laboratory infrastructure and equipment. Additionally, relative to the 
centralized testing paradigm, the POCT model requires that many more health 
care providers be trained to perform the required diagnostic assays. 
 In 2003, recognizing the constraints encountered during in the process of 
deploying and implementing diagnostic tests, the World Health Organization 
(WHO) published a set of criteria, the so called ASSURED criteria, for the 




one diagnostic test fall into three key characteristics (accuracy, accessibility, and 
affordability) and that trade-offs between these characteristics are often 
necessary and must be considered in the context of specific healthcare systems 
and use cases. The specific ASSURED criteria are as follows: Affordability, 
Sensitivity, Specificity, User friendliness, Rapid and robust, Equipment-free, and 
Deliverable to end-users.  
 When evaluating PCR-based diagnostic tests in the context of these 
ASSURED criteria, it is clear why these tests tend to be implemented largely in 
centralized testing laboratories rather than in POCT formats. As previously 
mentioned, PCR-based diagnostics offer both high sensitivity and specificity due 
to the sequence specific nature of the NAA process and has proven to be a 
robust process. The actual PCR can be completed in 30 minutes – 3 hours 
depending on the specific protocol, which can enable same day results in many 
contexts. Although PCR requires trained personnel, specialized and often 
expensive equipment, and cold chain support for reagents; these requirements 
are met in the centralized testing lab paradigm. However, when considering PCR 
for POCT applications, it is clear that the requirement for sophisticated 
equipment and need for trained personnel limits both the affordability and 
availability of PCR tests. Recognizing that the high accuracy and robustness of 
NAATs is ideal for diagnostic testing, alternative NAA chemistries and readout 
methods have been developed with the goal of reducing equipment requirements 




affordability of NAAT. 
All NAA techniques require the denaturation of nucleic acid template and 
amplicons in order to facilitate subsequent priming and amplification events. PCR 
achieves cyclical denaturation, priming and product elongation through the 
cyclical application of heat to samples. This process requires thermocycling 
equipment, which limits both the affordability and deliverability of PCR based 
tests in POC settings. In addition to PCR, a wide variety of additional NAAT 
modalities have been invented and adapted to clinical diagnostic use cases. A 
key feature of many more recent NAAT modalities is isothermal amplification. 
Rather than requiring temperature cycling equipment to facilitate thermal 
denaturation of amplicons (as is required by PCR), isothermal NAA methods 
implement a variety of biochemical mechanisms to induce amplicon denaturation 
at a fixed temperature which requires only an inexpensive heating element. 
Some commonly used isothermal NAA methods include: loop mediated 
isothermal amplification (LAMP)8, strand displacement amplification (SDA)9, 
helicase dependent amplification (HDA)10, recombinase polymerase amplification 
(RPA)11, nucleic acid sequence-based amplification (NASBA)12, rolling circle 
amplification (RCA)13. 
To further reduce equipment requirements, isothermal NAAT intended for 
POC use often employ readout methods that require only limited or no 
instrumentation. Inclusion of dsDNA specific fluorescent dyes is perhaps the 




reaction progress in real time or serve as end-point qualitative readouts, often 
using only naked-eye detection14. Some common NAAT readout modalities rely 
on the measure of endogenous markers such as turbidity15 and pH16 (via 
colorimetric dyes) that can also be used to monitor reaction progress in real time 
or serve as end-point qualitative readouts. Lateral flow immunoassay (LFIA) 
devices have also implemented for end-point visual readout of NAAT for POC 
applications and have offer the added benefit of multiplexed readout through 
spatially segregated detection lines17. 
1.2 Overarching goals, thesis aims and subsequent chapters 
 The purpose of this work was to develop both qualitative and semiquantitative 
methods for non-instrumented NAA testing suitable for the diagnosis and 
monitoring of infectious diseases in non-laboratory environments. Over the 
course of this work, I have developed assays using isothermal HDA chemistry 
with visual LFIA readouts to a number of infectious agents, though primarily for 
detection of the protozoan Trichomonas vaginalis (TV) which is the causative 
agent of the sexually transmitted disease (STD) trichomoniasis in addition to a 
separate assay for the semiquantitative detection of Hepatitis B virus (HBV). 
Specific information about these infections and their respective POCT needs are 
laid out in subsequent chapters. The following specific aims were proposed to 
address technical challenges associated with the development of qualitative or 
semiquantitative NAAT methods as well as challenges with raw input clinical 




Specific Aim 1 
Develop new and optimize existing thermophilic helicase dependent 
amplification assays for singleplex and multiplex detection of common 
sexually transmitted diseases and other infectious agents 
 I utilize isothermal thermophilic helicase dependent amplification (tHDA) to 
amplify target nucleic acid sequences from common infectious agents. Novel 
tHDA assays for the detection the protozoa Trichomonas vaginalis (TV), the 
causative agent of trichomoniasis, was developed and optimized for readout with 
simple visual lateral flow immunoassay. Existing assays for Neisseria 
gonorrhoeae and Chlamydia trachomatis were formulated for duplex, one-pot 
amplification. This work comprises chapter 2 of this document. 
Specific Aim 2 
Develop simple devices and protocols for the extraction and purification of 
nucleic acids from urogenital swabs and urine samples for STI detection 
I developed a strategy for the extraction of nucleic acids from urine samples 
mediated by electrostatic capture of DNA onto chitosan-functionalized 
membranes. Unlike precipitation-based approaches, this method proved to be 
compatible with urinary salts and demonstrated the capacity for enrichment of a 
low concentration DNA analyte in a large sample volume. DNA isolates from both 
strategies were demonstrated to be suitable for detection via helicase dependent 




Specific Aim 3  
Develop a nucleic acid amplification test and end-point visual readout 
strategy for the semiquantitative detection of Hepatitis B Virus DNA for use 
in chronic HBV case management 
While clinical treatment algorithms for many STIs consist of qualitative 
diagnosis and curative treatment (as is the case in NG, CT, TV, and GBS), 
infections such as chronic HBV require more a nuanced approach. While no 
curative treatment exists for chronic HBV infections, continuous antiretroviral 
therapy can be administered with the goal halting virion replication and 
suppressing viral load. As such, patients with chronic HBV infection require 
ongoing serial monitoring of HBV viral load levels to ensure that they are 
responding to treatment without the development of drug resistance. Here, I 
develop a novel NAAT in which input HBV DNA is effectively split into 
distinguishable nucleic acid species via ligation of oligonucleotide probes which 
can be independently amplified. By subjecting each ligation product to a different 
degree of competition for primers during isothermal HDA, I am able to establish 
an assay with multiple detection thresholds in a single reaction and readout. This 
method has been developed for simple, naked-eye visual readout via lateral flow 







Development of singleplex and duplex assays for the detection 
of Trichomonas vaginalis DNA using thermophilic helicase 
dependent amplification 
In this chapter, I first detail the development of a novel tHDA assay for the 
detection of Trichomonas vaginalis (TV) that was designed to integrate with an 
existing tHDA assay for the detection of Chlamydia trachomatis (CT) in a one-pot 
multiplex assay. This case study provides a useful reference for assay 
development of multiplexed isothermal NAATs that includes design criteria for 
singleplex tHDA assays and an overall methodology for testing multiplexed tHDA 
reactions. Additionally, I include a brief overview work done to  multiplexing 
existing CT and Neisseria gonorrhoeae (NG) tHDA assays, as this provides 
useful insights to assay failure modes that can arise during the development of 
multiplex isothermal amplification assays. 
I subsequently outline the development of a competitive internal control for the 
novel TV tHDA assay and provide an analytical characterization of this assay’s 
performance. In chapter 3, this work is further expanded upon as I demonstrate 
that this TV tHDA assay can be utilized for the detection of TV from urine 






Trichomoniasis and Trichomonas vaginalis 
Trichomoniasis is a sexually-transmitted infection (STI) caused by the 
protozoan Trichomonas vaginalis (TV). Globally, it has been estimated that each 
year 143 million new cases of Trichomoniasis18 occur, making Trichomoniasis 
the most common non-viral STI. In the US, 3.7 million people are thought to be 
infected with TV19; prevalence estimates in women have ranged from 3.1% up to 
8.7%20,21. Higher prevalence rates have been observed in STI clinic patients 
(26% of symptomatic and 6.5% of asymptomatic women22) and incarcerated 
persons (9%–32% of women21,23–25 and 2%–9% of men26,27). If left untreated TV 
infections can last for several months up to years20,28,29. TV infection has been 
associated with a variety of conditions including vaginitis, urethritis, cystitis and 
pelvic inflammatory disease and can also result in infertility30,31. Pregnant women 
with TV infection have increased risk of preterm delivery and low birth weight in 
addition to the risk of neonatal transmission30.  
People with TV infection are twice as likely to contract HIV32 and 3 times as 
likely to transmit HIV33. It is suspected that this increased risk of HIV contraction 
and transmission is in fact causal rather than a simple correlation; while further 
study is required, there is evidence which suggests that TV degradation to the 
vaginal epithelium, which serves as a natural barrier to infection, through the 
formation of mucosal haemorrhages, may be responsible for increased HIV 




vaginal epithelium and exocervix and men experience inflammation of the 
urethra; increasing the risk of microabrasions during intercourse35; which can 
further potentiate viral transmission. 
Although TV infection can result in host of medical issues and complications, 
the majority of infected individuals are, in fact, asymptomatic and are therefore 
unlikely to seek out screening or treatment. In one large study conducted on 
reproductive-age women in the United States, 85% of detected TV infections 
were from asymptomatic women20. Another study in a cohort of men with female 
sexual partners positive for TV infection found that, of 256 men who tested 
positive for TV, 77.3% were asymptomatic36. Asymptomatic infection are 
important for a two main reasons. First, individuals with asymptomatic infections 
may progress to symptomatic presentation; for example, roughly one third of 
women with asymptomatic infections identified by wet mount microscopy present 
with symptoms within 6 months of testing37. Second, asymptomatic individuals 
can continue to transmit TV to others38; thus detection and subsequent treatment 
of asymptomatic infections can help stymie TV transmission within the 
population. 
Once diagnosed, TV infections can be treated with a single dose of oral 
metronidazole or tinidazole. Historically, diagnosis of TV has been conducted via 
microscopic evaluation of genital secretions39; this approach offers high 
specificity (100%), but low sensitivity (44-68%) relative to other reference 




evaluation41; however, TV culture remains less sensitive than nucleic acid 
amplification tests (NAATs)39 and requires up to a week to complete. TV-specific 
antigen rapid detection tests, such as the Sekisui OSOM® Trichomonas Test, are 
available, but have limited sensitivity (83% vs. a composite reference standard of 
microscopy and TV culture42, both of which are less sensitive than NAATs), and 
are only suitable for vaginal swabs. 
NAATs have become the standard of care for TV detection due to their high 
sensitivity and specificity43. BD, Abbott, Hologic and others offer commercial 
assays and sample processing systems for TV detection from urine and swab 
sample types39,44. While these tests offer high performance, automated sample 
handling, and, in some instances, the ability to detect multiple pathogens, 
operational costs and equipment requirements have limited their use to batch 
testing in centralized laboratories. Point-of-care (POC) diagnostic tests could 
enable within-visit and possibly at-home testing and result in improved test-and-
treat strategies. In addition, POC tests can provide testing capability in clinical 
environments in which centralized testing is not feasible due to geographical or 
resource constraints. Some commercial NAATs, including the Xpert TV 
(Cepheid, Sunnyvale, CA) and the Solana Trichomonas Assay (Quidel, San 
Diego, CA), are suitable for near-POC use, but still require sophisticated 
instrumentation45. The Klapperich lab and others have demonstrated that 
isothermal NAATs, such as thermophilic helicase-dependent amplification (tHDA) 




cost heating systems46,47 and performed within paper-based analytical devices 
with lateral flow immunoassay (LFIA) readout48–50. 
Relative to comparable STIs such as Chlamydia trachomatis (CT) and 
Neisseria gonorrhoeae (NG), TV infections have historically been under-
diagnosed; this is due to a host of factors, including low sensitivity of traditional 
diagnostic procedures and a lack of routine screening programs51. The CDC 
currently recommends testing all women seeking care for vaginal discharge, 
routine screening in asymptomatic HIV-positive women, and to consider 
screening in persons at high risk for infection or in high-prevalence settings38. 
There is evidence today that attitudes within the medical community may be 
shifting towards the introduction of wider screening recommendations for TV 
infections52 from just small demographics to the public at large. Currently, both 
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) screening is 
recommended by the CDC for all sexually active women under the age of 25 and 
for women over 25 if in a high risk group53. Should TV screening 
recommendations be extended to the broader public, integration of a TV test 
alongside existing testing for CT and NG would enable widespread TV screening 
without requiring a substantial overhaul of existing screening programs 
infrastructure and work flows. To this end, a number of commercial NAATs for 
the concurrent detection of CT, NG, and TV, including the BD Max assay54. 
At the outset of this project, my efforts were focused on the development of a 




incorporating detection of NG as well. The work outlined within this chapter will, 
again, focus on the development of isothermal tHDA assays in the context of 
multiplexed pathogen detection. 
Helicase Dependent Amplification Operation and Design Principles 
Helicase dependent amplification (HDA) is an isothermal nucleic acid 
amplification technique first reported in 200410. Unlike PCR, which relies on 
temperature cycling to facilitate template DNA denaturation and primer 
annealing, HDA relies on the action of UvrD helicase, in conjunction with single-
stranded DNA (ssDNA)-binding protein (SSB) and an accessory protein MutL 
which stabilize ssDNA and enable helicase loading55 respectively, to achieve 
continuous denaturation of template DNA. Concurrently, DNA polymerase 
engages in elongation of hybridized primers, resulting in a continuous, 
exponential DNA amplification process which occurs at 37°C10. In 2005, 
development of a thermophilic HDA (tHDA), which facilitates amplification at 60–
65°C, was first reported. This advancement was enabled via substitution of the 
mesophilic UvrD helicase derived from E. coli for a thermostable homolog 
derived from Thermus thermophilius (Tte-UvrD) in conjunction with substitution of 
exonuclease- Klenow fragment of DNA polymerase I for Bst DNA polymerase, a 
strand displacing polymerase which is stable up to approximately 70°C56. 
Relative mesophilic HDA, tHDA exhibited more rapid amplification kinetics and 
obviated the need for both the MutL accessory protein as well as inclusion of 




commercially available HDA methods employ some variation of the tHDA 
scheme, using Tte-UvrD helicase and a variety of thermophilic or thermotolerant, 
strand displacing polymerases such as Bst and Gst DNA polymerase. 
Previously, our group demonstrated that a tHDA assay designed by Biohelix 
(primers sequences in table 1) was effective for the detection of C. trachomatis 
DNA in simulated samples containing elementary bodies captured on paper 
supports49.  
Assay oligonucleotides were formulated such that visual detection of the target 
amplicon, specific to a sequence within open reading frame (ORF) 3 of the C. 
trachomatis cryptic plasmid57, could be achieved via targeted accumulation of 
gold nanoparticles (AuNPs) on the test line of a lateral flow immunoassay (LFIA) 
device (figure 1). 
Table 1: C. trachomatis tHDA primer and probe oligonucleotides 
Oligonucleotide ID Sequence 
CT_ORF3 Forward Primer 5’-catgcaagatatcgagtatgcgttgtt-3’ 
CT_ORF3 Biotinylated Reverse Primer 5’-/Biotin/ctcataattagcaagctgcctcag-3’ 





As previously discussed, the goal of this work at outset was to integrate 
detection of both CT and TV into a single assay with the long term goal of also 
incorporating detection of NG for use in POC STI applications. Because the 
extensive prior work done to characterize this CT tHDA assay, I elected to use it 
as base upon which to build a multiplexed assay including detection of a TV 
specific target. While tHDA assays offer the benefit of reduced equipment 
requirements by obviating the need for thermocycling (required for PCR), they 
have certain drawbacks which make multiplexing assays relatively more 
challenging. Specifically, tHDA has a known tendency to produce nonspecific 
primer-dimer artifacts58. Though efforts have been made to formulate a general 
solution to eliminate amplification artifacts in tHDA using primers containing self-
avoiding nucleotide analogues59, their effect can generally be mitigated through 
careful primer design complemented with empirical testing. Thus, criteria for 
Figure 1: CT ORF3 tHDA amplicons and visualization via lateral flow immunoassay. 
(A) By including biotinylated reverse primer in excess of the forward primer, ssDNA 
amplicons are formed which can hybridize in a sequence specific manner to FAM-
labeled probe oligonucleotide. (B) Dual-labeled tHDA amplicons can cause visible 
aggregation of gold nanoparticles (AuNPs) on antibody test lines; appearance of a 





evaluating potential TV assays for inclusion in the multiplex assay include 
elements specific to the TV target (e.g., acceptable sensitivity and specificity) as 
well as compatibility with the existing CT assay (e.g., infrequent to no primer 
dimer artifacts, lack of cross-talk with LFIA readout). 
2.2 In silico design of potential TV tHDA assays 
General strategy for development of TV tHDA assays 
With these performance criteria in mind, a general strategy for evaluation of 
TV assay was developed (figure 2). First, consensus sequences for three high-
copy repeated genomic loci within the TV genome were identified as candidates 
for assay development. Next, suitable subsequences from these gene regions for 
tHDA primer and probe design were identified using Primer3 and recommended 
tHDA primer and probe design parameters. Next, because these assays were 
designed from consensus sequences, individual repeat regions within the 
genome were scanned for the presence of the potential primer pairs and probe 
sequences comprising each potential assay to generate an estimated copy 
number for each assay. Finally, a set of high copy number assays were selected 
for in vitro testing; first as singleplex assays to verify successful TV detection and 
then successful assays were tested for compatibility in the TV CT duplex format. 




From this process, a single TV assay was selected and successfully incorporated 
into a duplex format with the CT ORF3 assay. 
Selection of target genomic loci 
While reviewing these existing NAATs for detection of TV, it became apparent 
that the most commonly used genomic measurand sequences were selected 
from within highly conserved, high-copy number genomic repeat sequences 
contained in the TV genome. Sequencing by Carlton et al. in 2007 revealed that 
at least 65% of the approximately 160 Mb TV genome consists of repetitive 
sequences60. The highly repetitive nature of the TV genome was first noted in a 
1984 publication by Wang and Wang where restriction digestion of genomic TV 
DNA was found to result in the formation of distinct banding patterns rather than 
smears61. In the following years, other groups successfully cloned and 
sequenced a number of these genomic repeat sequences62–64 and took 
advantage of their high copy numbers for sensitive TV detection by fluorescence 
in situ hybridization63 and PCR64. These repeated genomic sequences first 
reported in the early 1990s were used in 2013 by Bandea et al. to develop 
sensitive nested PCR assays for the detection of TV in noninvasively collected 
urine samples65. Selection of a highly multicopy target sequence offers the 
benefit of increased analytical sensitivity (on a per trichomonad basis) and thus I 
chose to use these same three reported genomic repeat consensus sequences 




Table 2: Characterized genomic repeat regions in the TV genome 
Repeat GenBank accession number Length (bp) Reference 
L23861 1019 64 
M86482 701 63 
X83109 589 62 
 
Consideration of helicase homing 
With these sequences in hand, I next went about finding subsequences within 
the larger repeat regions which were suitable for tHDA assay development. 
However, before identifying specific primer and probe sequences from within the 
genome, some consideration of initiation of the tHDA process from genomic 
targets was taken into account. The Tte UvrD helicase used in tHDA is known to 
unwind 3’-tailed, 5’-tailed, and blunt ended dsDNA substrates56. It is this activity 
on blunt dsDNA products that provides the required denaturation in the tHDA 
process. Known measurements of monomeric Tte UvrD processivity have varied 
across studies (769 ± 1 nt 66, 2400 ± 600 nt 67, 1260 ± 60 nt68), but all indicate 
that, while Tte UvrD is suitable for denaturing short tHDA amplicons, it should 
theoretically have some difficulty denaturing genomic loci which are contained 
within long stretches of genomic DNA. This issue can be subverted by using a 
strategy known as helicase homing where a short segment of chromosomal DNA 
containing the tHDA target sequence is excised using restriction endonuclease 





mediated helicase homing has been shown to significantly reduce threshold time 
in tHDA reactions69. To be of practical use, selected restriction endonucleases 
must cut relatively close to the target locus without activity within the target 
sequence or internal control sequence and retain activity in the tHDA reaction 
buffer; ideally, such enzymes should also have rapid kinetics (i.e. NEB “time-
saver qualified enzymes”)69. Commercially available enzymes (available through 
New England Biolabs) which resulted in multiple cut sites within each of the 3 
selected genomic repeat sequences were identified (table 3) and the resulting 
digestion product sequences were considered for tHDA assay development. 
Restriction enzymes were additionally screened for compatibility with the existing 
CT tHDA product to ensure that no unintended degradation would occur. 
  





% Activity in NEB Buffer Inactivation 
Temperature 
Incubation 
Temperature 1.1 2.1 3.1 CutSmart 
ApoI Yes 10 75 100 75 80°C 50°C 
BssKI Yes 50 100 100 100 80°C 60°C 
BstNI Yes 10 100 100 75 No 60°C 
FatI NO 10 100 50 50 80°C 55°C 
Hpy166II Yes 100 100 50 100 65°C 37°C 
HpyAV Yes 100 100 25 100 65°C 37°C 
HpyCH4III NO 100 25 10 100 65°C 37°C 
HpyCH4IV Yes 100 50 25 100 65°C 37°C 
MmeI Yes 50 100 50 100 65°C 37°C 
PspGI NO 25 100 50 100 No 75°C 
RsaI Yes 25 50 10 100 No 37°C 
ScrFI NO 100 100 100 100 65°C 37°C 
SspI Yes 50 100 50 50 65°C 37°C 




tHDA primer and probe design parameters 
Digest products, each bookended by identical restriction enzyme recognition 
sequences, from each of the 3 genomic repeat sequences larger than 70 bp 
were considered as template for assay development. Potential tHDA primer pairs 
and probe sequences were identified in these restriction digest products using 
Primer 3 software70. Design parameters were selected as per recommendations 
from BioHelix Corporation, specifically: product size was limited to 70 – 120 bp, 
primer size was specified to range from 20 – 35 nt with an optimum of 25 – 27 nt; 
primer melting temperature was set to 60 – 80°C with an optimum of 68 – 72 °C, 
primer GC content was set to 30 – 60%, and all other parameters were left at 
their default settings71. While the manufacturer does not specify an optimal 
binding temperature for the internal hybridization probe required for lateral flow 
readout, based on past experience, probe hybridization temperature was 
specified to be approximately 5°C lower than either corresponding primer. In 
principle, this hapten probe melting temperature only needs to be high enough 
such that sufficient hybridization between the probe and its intended product can 
occur under the conditions of the LFIA readout, assumed to be room 
temperature. Others have shown that probe melting temperatures as low as 36°C 
are suitable for LFIA detection of tHDA products72. 
Validation of potential assays with TV genomic sequence data 




smaller subsequences from which many potential assays (each consisting of 2 
primers, an internal probe sequence, and up and downstream restriction loci) 
were generated. However, because the reference sequences to generate these 
potential assays are consensus sequences, they do not encompass the 
variability that exists across individual instances of each repeat across the TV 
genome that could result in amplification failures. Accordingly, the available 
sequence data for the TV genome60 was scanned for individual instances of each 
potential assay using a Python script. Rather than scanning the entire TV 
reference genome, contigs identified by BLAST73 to have high similarity to any of 
the 3 repeat consensus sequences were examined. Each of these contigs were 
examined for instances of each primer pair within a specified distance to ensure 
that resulting products were within the 70-120 bp range demonstrated to amplify 
efficiently by tHDA. If an instance of the given primer pair was observed, 
presence or absence of the corresponding probe oligonucleotide between the 
primers was examined. Additionally, presence or absence of both upstream and 
downstream instances of the appropriate restriction enzyme endonuclease 
recognition sequence within 200 bases of either primer was also examined. 
Lastly, the amplicon sequence was scanned for any instances of the appropriate 
restriction enzyme recognition sequence to ensure that degradation of the 
amplicon would not occur. 
Ultimately, 24 potential tHDA primer pairs were considered for in vitro 




enzymes contained some shared sequences, considerable overlap in the 
potential assays identified by Primer3 across products was observed. While the 
majority of assays selected were predicted to have many “high quality” amplicons 
(i.e. amplicons with both primers, the probe hybridization sequence, and both up 
and downstream restriction digest loci), a few were included from repeats L23861 
and M86482 which had poor helicase homing or internal restriction as inclusion 
of restriction enzymes in tHDA is not strictly necessary and assays from these 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3 Materials and Methods 
DNA Templates 
 Genomic DNA: Genomic TV DNA was purchased from ATCC (Manassas, VA; 
strain G3 Cat no. PRA-98D). While the exact size of the TV genome is unknown 
due to issues associated with the high degree of redundant sequences in its 
genome, it is estimated to be approximately 160 Mb60. Given that the average 
mass for a base pair is 650 Daltons, I estimated the mass of the TV genome to 
be 172.7 fg. For the sake of comparison to existing assays, which report 
sensitives on the basis of individual trichomonads, I define 1 genomic mass 
equivalent to be equivalent to 172.7 fg of Trichomonas vaginalis (strain G3) DNA. 
Additionally, genomic DNA was extracted from Trichomonas tenax (ATCC 
30207) using a Qiagen Blood and Tissue kit (Germantown, MD). DNA isolated 
from an additional 11 likely commensal organisms (Atopobium vaginae, 
Bacteroides fragilis, Chlamydia trachomatis (serovar L2), Escherichia coli, 
Fusobacterium nucleatum, Gardnerella Vaginalis, Herpes Simplex Virus 1, 
Herpes Simplex Virus 2, Neisseria gonorrhoeae, Staphylococcus epidermidis, 
and Ureaplasma urealyticum) was kindly supplied by the Johns Hopkins Center 
for the Development of Point of Care Tests for Sexually Transmitted Diseases. 
 Control Plasmid DNA Template: All control plasmids were produced using a 
pGem T-Easy parental vector (Promega), with template sequence inserts 




contained in the multiple cloning site using standard cloning techniques. The TV 
control plasmid includes full-length copies of 3 high-copy genomic repeats 
(Genbank accession nos. L23861, M86482, X83109). 
Nucleic acid amplification by tHDA 
 tHDA reagents: All tHDA reactions were conducted using reagents from the 
IsoAmp® III Universal tHDA Kit (Quidel Corporation, San Diego, CA). Realtime 
detection of nucleic acid amplification by both tHDA and PCR was monitored 
using EvaGreen (Biotium, Fremont, CA) with ROX Reference Dye (Invitrogen, 
Carlsbad, CA) used as a passive reference dye. Realtime reactions were 
performed on either a Quantstudio 5 Real-Time PCR System (Applied 
Biosystems, Foster City, CA) or an Applied Biosystems 7500 Real-Time PCR 
System. tHDA reactions were conducted either as a 25 µL one-step or 50 µL 
two-step reaction. 
Two-step tHDA Protocol: The two-step tHDA reaction protocol is designed to 
promote primer hybridization to target sequences within long stretches of 
genomic DNA that may otherwise be inaccessible due lack of denaturation by Tte 
UvrD helicase. In a given reaction using this two-step protocol, template DNA is 
added to mastermix Mix A (1X Annealing buffer II, 240 nM reverse primer, 80 nM 
forward primer) in a 25 µL final volume. Mix A is then incubated at 95°C for 2 
minutes before immediately chilling on ice to promote denaturation of the 




template. Next, 25 µL of Mix B (1X Annealing buffer II, 8 mM MgSO4, 80 mM 
NaCl, 0.4X EvaGreen® dye, 80 nM ROX reference dye, 3.5 µL of IsoAmp® dNTP 
solution, and 2 µL of IsoAmp® III Enzyme Mix) is added to Mix A, and mixed by 
pipetting on ice to mitigate nonspecific amplification by the DNA polymerase 
used in the tHDA reaction. 50 µL of completed mastermix are then pipetted into 
to appropriate wells of a 96 well plate, again on ice, before overlaying reactions 
with 50 µL of mineral oil and sealing the plate prior amplification. Reactions are 
then incubated on a thermocycling instrument for 60 – 100 minutes at a constant 
temperature of 65°C. 
One-step tHDA protocol: While the two-step tHDA protocol is beneficial for 
ensuring that initial primer annealing occurs on template DNA, this process is 
relatively complex and in principle less favorable for POCT applications than a 
one-step tHDA protocol where only a single mastermix solution and single 
incubation temperature is required. This one-step procedure was ultimately used 
far more frequently and, over the course of this work, reagent concentrations 
were adjusted to reduce required reaction time and promote consistent 
performance. The following conditions were found to be the most optimal for the 
assay tested. One-step tHDA mastermix was prepared on ice; the mixture 
consists of tHDA reagents (1X Annealing buffer II, 4.8 mM MgSO4, 35 mM NaCl, 
0.2X EvaGreen® dye, 40 nM ROX reference dye, 1.75 µL of IsoAmp® dNTP 
solution, and 2 µL of IsoAmp® III Enzyme Mix added just before amplification to 




oligonucleotides. Concentrations of primer and probes were varied over the 
course of the project and depended on the number of orthogonal amplification 
targets (i.e. targets with unique primer sequences) included. For singleplex 
reactions, 120 nM biotinylated primer with 40 nM each unlabeled primer and 
hapten probe was found to be suitable. For duplex reactions, 60 nM of each 
biotinylated primer, and 20 nM for each unlabeled primer and hapten probe was 
found to enable co-amplification of 2 tHDA products. 
In later experiments, including limit of detection analysis for the standalone TV 
assay with internal control Ficoll 400 (Sigma, BioXtra grade) was included at a 
10% final concentration. The addition of this molecular crowding agent was 
observed to dramatically decrease tHDA doubling times enabling faster 
amplification, in agreement with existing literature69. As a cautionary note, 
several other grades (i.e. not BioXtra) of Ficoll 400 included in attempted 
experiment were found to inhibit amplification via tHDA (data not shown). 
Additionally, inclusion of the mineral oil overlay was also excluded for one-step 
tHDA reactions without noticeable impact on assay performance. 
One-step tHDA reactions were again carried out at 65°C with incubation times 
ranging from 30 minutes to 1 hour depending on specific circumstances; 
reactions tested during characterization of the standalone TV assay with internal 





Endpoint Detection of tHDA Amplicons by LFIA and PAGE 
 Lateral Flow Immunoassay (LFIA) Readout: Biotinylated single-stranded tHDA 
products are formed when excess biotinylated reverse primer is used in a tHDA 
reaction. Biotinylated tHDA product can bind in a sequence specific manner to 
either the fluorescein (FAM) tagged TV probe, or to the digoxigenin (DIG) tagged 
TVIC probe. tHDA product was run on commercial LFIAs (D003-05, USTAR 
Biotechnologies, Hangzhou, China) which contain anti-FAM and anti-DIG test 
lines in addition to an anti-streptavidin control line. 4 μL of tHDA product is 
applied to the LFIA and 2 drops of running buffer are applied to drive wicking flow 
through the LFIA strip. The biotin-tagged tHDA products bind to streptavidin-
coated gold nanoparticles and then pass over anti-FAM and anti-DIG antibody 
test lines where they can bind specifically and accumulate. Any unbound gold 
nanoparticles are then captured on an anti-streptavidin antibody control line. 
Visible accumulation of gold nanoparticles at the test lines is used to interpret the 
test. LFIA strips were imaged (DS-Ri2, Nikon, Minato, Tokyo, Japan) and test 
line densities were quantified using ImageJ (NIH, Bethesda, MD); test lines were 
considered positive if their intensity was >10% of the intensity of the control line. 
 Polyacrylamide gel electrophoresis (PAGE): Following amplification, 4 µL of 
tHDA product is mixed with 2 µL of 6X gel loading dye (New England Biolabs, 
B7024S) and loaded into wells of an 8% polyacrylamide gel. Gels are cast in-
house and allowed to polymerize for at least 1 hour before use. Samples were 




90V. Gels were then incubated in 30 mL of 1X SYBR™ Green dye (Invitrogen) 
before imaging on either a Versadoc Imaging System (BioRad) or a ChemiDoc 
MP Imaging System (BioRad).  
Statistical Analysis 
Determination of TV/TVIC tHDA assay limit of detection (LOD): The TV/TVIC 
assay was conducted with 100 copies of the TVIC control plasmid per reaction 
and with varying amounts of TV genomic DNA (10 – 10-4 genomic mass 
equivalents per reaction or no TV genomic DNA) and amplified for 30 minutes at 
65°C using a one-step tHDA protocol. tHDA product was tested via LFIA and 
presence or absence of the TV test line (anti-FAM) was recorded. In total, 9 
replicates were performed at each concentration tested, and binary detection 
results were fit to a probit regression using MATLAB. The reported LOD value is 






2.4 Results and Discussion 
Singleplex tHDA detection of TV 
In addition to eventually demonstrating compatibility with the existing CT 
ORF3 tHDA assay, an ideal TV assay would amplify relatively quickly in the 
presence of template and would not amplify in absence of template. Prior to 
multiplexing attempts, all 24 potential TV tHDA assays were tested in two-step, 
singleplex tHDA reaction format to verify if successful amplification could be 
achieved with each primer pair, and, if so, to assess the rate at which detectible 
amplification was achieved (measured by the threshold time Tt). Realtime data 
were collected to determine amplification threshold times when 1000 genomic 
mass equivalent of TV DNA was present in each reaction. To serve as a positive 
amplification control, 10^6 copies of a control plasmid containing a sequence 
from the porA pseudogene of NG was used as template for a previously 
characterized tHDA assay for detection of NG48. No template control conditions 
were used for each of the potential TV assays as well as the NG control reaction.  
While there were several instances in which the NG no template control 
resulted in amplification of NG product (presumably due to carry over 
contamination), useful performance data for the potential TV assays was 
obtained. Of the 24 assays examined, 22 resulted in successful amplification of 
products of the expected size (Figure 3). A wide range of amplification threshold 









was achieved, presumably due to differences in genomic copy number for each 
assay’s respective target sequence and differences in amplification efficiency of 
the given primer pair. In total, 10 of the assays tested achieved detectible 
amplification within 30 minutes and only 7 assays demonstrated any background 
amplification in the absence of template within the first 60 minutes of the 
incubation (Table 5). Ultimately, assays A, E, G, P, Q, and W were selected for 
further development by incorporating FAM labeled internal probes and a 
biotinylated reverse primers for LFIA readout. 




Lateral flow detection of TV tHDA products 
Ultimately, my goal was to achieve visual co-detection of hapten-labeled CT 
and TV tHDA amplicons via using commercially available LFIA test strips with 
anti-DIG and anti-FAM test lines respectively (Figure 4). While CT products had 
previous been detected using a FAM-labeled probe, this was easily converted to 
DIG as a matter of cost savings (Figure 5). With this conversion of CT detection 
from the FAM line to the DIG line completed, 3’-FAM labeled probes and 
biotinylated reverse primers for potential TV assays A, E, G, P, Q, and W were 
tested in two-step tHDA reactions using both genomic TV DNA (gTV) as well as 
TV control plasmid DNA (pTV) as template. Post tHDA product from each assay 
was applied to lateral flow strips containing an anti-FAM test line and an anti-
streptavidin control line (Figure 6).  





Figure 5: Conversion of CT probe from FAM to DIG 




While visual banding was observed in all instances when template was 
present for each assay, assays A, E, P, and W each displayed some faint 
banding in the anti-FAM test line in the absence of template. This light false 
positive signal generation could be explained by either the formation of an 
amplification artifact which contains both the biotinylated reverse primer and the 
FAM-labeled internal probe oligo or perhaps, due to some minor unintended 
hybridization between the biotinylated reverse primers and their respective FAM 
probes directly. In contrast, assays G and Q did not display any detectible false 
positive signal formation in their no template control (NTC) conditions while 
retaining strong test line signal in the presence of template. 
Testing of potential TV assay in duplex format with the CT tHDA assay 
Having demonstrated adequate detection of TV genomic DNA via gel and 
LFIA readouts performances of potential TV assays A, E, G, P, Q, and W were 
examined when these assays were performed in one pot with the existing CT 
tHDA forward and reverse primers (table 1). Rather than focusing immediately on 
codetection of both CT and TV DNA targets, my initial aim was to simply see if 
amplification of a single target, in this case CT, could be achieved in a duplex 
format without the unwanted aggregation of primer dimer artifacts. To simplify the 
assay preparation procedure, the original two-step tHDA protocol was 
transitioned into a one-step protocol where priming of the template DNA occurs 
during the tHDA incubation, rather than during a pre-incubation melting step71. 




of the CT tHDA assay (data not shown). One-step tHDA reactions were 
performed with CT tHDA primers in tandem with primers from each of the 
examined TV tHDA assays as described in the materials and methods section 
(Figure 7).  
 Of the TV primer pairs tested, only assay A demonstrated complete 
incompatibility with the existing CT tHDA assay, as evidenced by the formation of 
apparent primer-dimer artifacts in both the pCT positive and NTC conditions. 
Some amplification events were observed in the NTC conditions when assays P, 
Q, and W were tested in duplex with the CT primers and a second, unexplained 
product was formed when primers from assay E were included in the assay in the 
presence of pCT template DNA. I selected TV assay G as a candidate for further 
multiplexing studies as this assay demonstrated high sensitivity for TV DNA with 
Figure 7: Amplification of pCT control DNA with CT ORF3 primers in duplex format 




easily visualized lateral flow readout, little to no background amplification in the 
absence of template, and no apparent unwanted interactions with the existing CT 
tHDA assay when run as a duplex. 
Over the course of developing the CT/TV duplex assay and optimizing run 
conditions for a similar CT/NG duplex assay, a number of reaction parameters 
which can influence the success or failure of a given duplex amplification reaction 
became apparent. For instance, tHDA reaction efficiency is known to be a 
function of primer concentration69; increasing primer concentration tends to 
increase amplification efficiency, but also increases incidents of primer dimer 
aggregation. This increase in amplification efficiency was observed in my control 
condition where double the amount of CT assay oligos were used (“CT + CT”) 
relative to the control condition (“CT + Blank”), with the former achieving a 
threshold time of 26.5 minutes while the latter was only detected after 95.7 
minutes. Curiously, all duplex assay formulations used the same concentration of 
CT oligonucleotides as did the CT + Blank control conditions, but all resulted in 
substantially lower threshold amplification times. This finding suggests that total 
oligonucleotide concentration present in a given tHDA reaction may influence 





Demonstration of duplex detection of CT and TV DNA by tHDA and LFIA 
 Primers and probes for the CT OR3 and TV G tHDA assays were used to 
prepare tHDA mastermix using a one-step formulation. The duplex assay was 
tested in the presence control plasmids specific to the CT and TV targets 
individually and in combination before readout using PAGE and LFIA. PAGE 
results (Figure 8) and corresponding LFIA results (Figure 9) both demonstrate 
successful detection of the CT and TV target sequences individually and in 
combination. When template sequences for each respective assay target are 
presented individually, strong banding the corresponding LFIA test line is 
observed. When both the CT and TV template sequences are presented in 





tandem, both the CT and TV tHDA amplicons can be easily observed via gel 
electrophoresis, however, detection of the CT-specific DIG test line in LFIA is 
noticeably more faint than when TV template is absent. This signal decrease is 
due, at least in part, to the fact that post-tHDA samples applied to the LFIA 
device first encounter the anti-FAM test line before advancing to the anti-DIG test 
line. Because both the CT and TV tHDA amplicons bind to the streptavidin-
coated AuNPs contained in the conjugate release pad of the LFIA strip, a large 
portion of AuNPs which could otherwise hybridize to the anti-DIG test line via CT-
specific tHDA amplicons are sequestered on the anti-FAM test line. In principle, 
this issue could be obviated by decreasing the affinity for the FAM-labeled TV-
specific tHDA products through reduction of Anti-FAM antibody concentration on 
the first test line74 or, more simply, through reduction of the FAM-labeled probe 
oligonucleotide in order to bias the readout towards detection of the DIG-labeled 
CT-specific tHDA amplicon. This however, was not pursued during the course of 
this work. While the CT/TV duplex tHDA assay was never fully characterized, this 
work provides a useful case study of tHDA primer and assay design especially as 
Figure 9: LFIA readout of CT and TV templates amplified individually and in 




it relates to the development of multiplexed assays. In addition to this work, I 
engaged in efforts to modify tHDA reaction parameters to permit the multiplexing 
of an existing assay for NG48 with the same CT assay. The following section 
includes highlights from this work highlights and few technical considerations 
which are broadly relevant to multiplexed tHDA design. 
tHDA mastermix formulation and multiplexing 
 When multiplexing isothermal assays for multiple targets, in addition to the 
considerations related to compatibility of individual primers included in the 
reaction, it is also necessary to consider how the amplification of multiple 
amplicons may strain consumable assay reagents. Unlike PCR, where the 
energy required for denaturation of amplicons is supplied to the reaction via an 
external heating element, in many isothermal NAA techniques this energy 
required for denaturation is supplied from a biochemical source. For example, in 
loop-mediated isothermal amplification (LAMP), denaturation of template and 
amplicons is achieved through the strand-displacing action of Bst polymerase, an 
activity that is powered by energy from the hydrolyzation of dNTPs into 
polymerized DNA and pyrophosphate. The elegant design of the LAMP method 
couples the generation of energy required for strand displacement directly to 
polymerization of LAMP amplicons. In other isothermal NAA techniques, such as 
tHDA and recombinase polymerase amplification (RPA), energy for the 
denaturation of amplicons is derived from the hydrolysis of nucleotide and/or 




tHDA56 and uvsX recombinase in RPA75. Unlike LAMP however, the triphosphate 
energy sources are consumed continuously in the presence of suitable DNA 
substrates by both Tte UvrD helicase and uvsX recombinase.  
Thus, in addition to primers and dNTPs (those used for amplicon formation), 
dATP required for action of the Tte UvrD helicase may also become a limiting 
reagent when attempting to form multiple, orthogonal products, especially when 
threshold amplification times for said products differ substantially due to 
differences in template concentrations, relative amplification efficiencies, or both. 
 In order to achieve successful duplex detection of both the CT and NG DNA 
template target sequences when the former was present at a 100-fold higher 
concentration, a reduction in total primer concentration from my standard 
operating concentration was necessary (Figure 10). 
By reducing the concentration of both the CT and NG biotinylated primers from 
90 nM to 60 and the unlabeled primers for each target from 30 nM to 20, co-
amplification of both the CT and NG tHDA amplicons was observed by PAGE 
with corresponding readouts using LFIA devices. As before, reduction of primer 
concentrations was associated with considerable increases in tHDA threshold 
amplification times for both assay targets. As such, given that low sample-to-
answer times are desirable for POCTs, especially for infections such as CT and 
NG where single visit test and treat interventions are possible, reduction of total 




primer-limited rather than limited by another reagent. I explore this topic in 
greater detail in chapter 4; I observed that addition of supplemental dATP is 
highly effective at recovering amplification of multiple tHDA products especially in 
instances when template concentrations for each product differ substantially. 
 
Characterization of the TV tHDA assay with a competitive internal control 
 While achieving co-detection of TV alongside other STIs pathogens is an 
important goal which could increase screening availability by leveraging existing 
testing regimens; another desirable feature for POCT for detection of STIs is a 
mechanism by which one can differentiate true negative and false negative test 
Figure 10: A decrease in total oligonucleotide concentration yielded successful 
amplification of both CT and NG template sequences when the former was present 





results. The TV tHDA assay is a signal-on style test, meaning, that generation of 
a test line signal, via the accumulation of visible gold nanoparticles on the LFIA 
device, is used to assign a TV positive label to a given sample. The underlying 
assumption with this assay, and NAATs at large, is that the absence of signal 
generation when a given sample is tested with the assay indicates that the 
sample being tested is either negative for TV DNA, or that the sample has a 
relatively low concentration of measurand DNA below the detection threshold of 
the assay. However, consider a hypothetical instance in which the presence of a 
substance which inhibits the tHDA process (e.g. excess salt) is present in a given 
sample. In such a case, one would expect a lack of signal generation on the LFIA 
device during the readout phase of the assay, irrespective of the presence or 
absence of TV DNA template in the given sample. This is one of many 
circumstances which can give rise to false negative test results, when a sample 
containing detectible levels of target is incorrectly labeled as negative due to 
factors which prohibit proper conduction of the assay. This consideration merits 
concern given that a wide variety of substances present in both clinical samples 
and common nucleic acid extraction reagents are known to cause inhibition of 
NAATs. 
 A simple method for obviating issues associated with false negative tests is 
the inclusion of a control reaction which can occur alongside detection of the 
desired assay target, in this case TV DNA. To address this need, I designed a 




control is considered competitive because amplification of a TV internal control 
(TVIC) product, from a plasmid DNA spiked into each tHDA reaction at a known 
concentration (pTVIC), utilizes the same primers as the TV tHDA assay. While 
the TV and TVIC products are bookended by identical sequences, their internal 
sequences differ and can therefore be probed and differentiated again using 
LFIA (Figure 11). 
 Because the assay is competitive, amplification of the control product can 
prohibit detection of TV target DNA if the control plasmid is present at a high 
concentration. Thus, the TVIC plasmid should be used included at a 
concentration which is just high enough to ensure consistent amplification and 
detection as excess of this plasmid could lower the sensitivity of TV DNA 
detection. Initial testing with the TV/TVIC duplex assay revealed that reliable and 
consistent detection of the TVIC product could be achieved using as little as 100 
copies of the TVIC control plasmid per tHDA reaction (data not shown).  




With mastermix parameters set for the TV/TVIC duplex assay, analytical 
sensitivity of the assay was tested using serially diluted genomic TV DNA as 
template (Figure 12).  
 Reliable detection of TV DNA was achieved down to 0.1 genomic mass 
equivalents of TV DNA. No instances of false positive detection of TV were 
observed in the NTC conditions. Lateral flow test results were fitted to a probit 
model to approximate the limit of detection for the assay, assumed to be the 
lowest TV DNA concentration at which 95% of samples would be expected to 




return a positive test result. This value was found to be 0.2 TV genomic mass 
equivalents. 
 In addition to analytical sensitivity, a preliminary in vitro study of assay 
specificity was conducted by attempting to amplify nucleic acid from 11 
commensal organisms which may be present in clinical samples being tested for 
TV, as well as DNA from a related Trichomonas species, T. tenax (table 6). 
On the whole, the TV tHDA assay displays good specificity for its intended 
target. Of particular note, no cross reactivity was observed with DNA from T. 
tenax, a phylogenic near neighbor of TV, suggesting that the selected 
measurand sequence of the TV assay is not likely to interact with other members 
of the Trichomonas phylum .Of the species tested, only DNA derived from A. 
vaginae and U. urealyticum displayed instances of cross-reactivity with the TV 
tHDA assay when tested with LFIA (figure 13). The only instance of signal 
 
Species (ATCC Designation) TV POS by LFIA 
A. vaginae (BAA-55) ( –  / –  / + ) 
B. fragilis (25285) ( –  / –  / –  ) 
C. trachomatis serovar L2 (VR-902B) ( –  / –  / –  ) 
E. coli (11775) ( –  / –  / –  ) 
F. nucleatum (25586) ( –  / –  / –  ) 
G. vaginalis (49145) ( –  / –  / –  ) 
Herpes Simplex Virus 1 (VR-260) ( –  / –  / –  ) 
Herpes Simplex Virus 2 (VR-540) ( –  / –  / –  ) 
N. gonhoroeae (19424) ( –  / –  / –  ) 
S. epidermidis (14990) ( –  / –  / –  ) 
*T. tenax (30207) ( –  / –  / –  ) 
U. urealyticum (27618) ( –  / + / + ) 




generation in A. vaginae was considerably faint, and possibly an anomalous 
result. More concerning, was the noted cross-reactivity with U. urealyticum DNA 
which resulted in dark banding on the TV test line on LFIA readout. Only faint 
banding was observed on PAGE with products larger than either of the expected 
amplicons for TV and TVIC suggesting that their amplification was not due to 
carry over contamination from past work with TV or TVIC tHDA products. Of 
note, the TVIC control plasmid was omitted from this study in order to determine 
if crosstalk with either the TV or TVIC products. Upon retesting the U. 
urealyticum DNA with the TV/TVIC duplex assay in the presence of 100 copies of 
the TVIC plasmid, only DIG test line banding was observed, suggesting that 
crosstalk tHDA products from U. urealyticum DNA could be out-competed by 
amplification of the TVIC product in the standard assay formulation. 
 






The work outlined in this chapter demonstrates the success of multiplexing 
various tHDA assays for co-detection of multiple pathogens in addition to 
detailing the development of a sensitive, specific, and internally controlled assay 
for the detection of TV DNA. This work is further expanded upon in chapter 3, 





Chapter Three  
Rapid and low-cost strategy for DNA enrichment from urine 
samples for sensitive detection of Trichomonas vaginalis 
3.1 Significance 
While a great deal of advancement in NAAT and, more broadly, molecular 
biosensing technologies occurred over the past three decades, sample 
preparation techniques required to prep clinical specimens for NAAT lagged 
behind. As such, upstream sample preparation has been referred to as the 
“forgotten beginning”76. The objectives and constraints for clinical sample 
preparation methods vary widely and depend on factors including the nature of 
the sample matrix, the target analyte, the composition of the sample matrix, the 
concentration of the analyte in solution, and the downstream detection method to 
be implemented to detect the target analyte. 
In the context of STI detection, the sample types most commonly tested are 
swab based samples (e.g. vaginal and urethral swabs) and urine. While vaginal 
and urethral swabs are used for TV testing, the use of first void urine samples for 
testing is preferred by many patients, and in many clinical centers gonorrhea and 
chlamydia are primarily diagnosed from urine 77–79. Testing men is an emerging 
goal in patient communities with high rates of STIs80, and men also prefer non-
invasive collection of a urine sample to a urethral swab80. 




on silica, electrostatic interactions between DNA and positively charged 
substrates, oligonucleotide probe mediated sequence-specific capture, or 
capture of cells or microorganisms prior to lysis to increase DNA concentration. 
While widely used, solid phase DNA extraction requires nonpolar solvents and 
chaotropic agents, which are known to inhibit NAATs and require extensive 
washing procedures to recover performance. To avoid complications from NAAT 
inhibitors, many groups have implemented electrostatic DNA enrichment 
strategies in which negatively charged nucleic acids are captured on positively 
charged substrates. Some substrates, such as chitosan, exhibit controllable 
surface charge. The DNA binding ability of chitosan can be switched on or off by 
changing the pH of the carrier solution, with protonation of the primary amine of 
chitosan conferring the molecule with a positive charge under light acidic 
conditions. 
Chitosan has been widely implemented in electrostatic DNA capture strategies 
due to its charge-switching behavior. Cao et al. were the first to demonstrate that 
chitosan-coated beads could be used to controllably capture and release DNA 
through pH dependent charge switching in a microfluidic device81. Since then, 
other groups have demonstrated DNA enrichment from dilute samples on 
chitosan-functionalized magnetic beads which can be used directly in PCR82. 
Byrnes et al. demonstrated capture and over 12-fold enrichment of DNA using 
chitosan-functionalized nitrocellulose and glass membranes and demonstrated 




matrices containing blood and mucins83. Gan et al. used a chitosan-
functionalized filter housed in a thermoplastic device to couple electrostatic DNA 
capture and in situ PCR amplification, eliminating the need for DNA elution, and 
demonstrated isolation of DNA from whole blood84. Using a chitosan-coated 
nylon membrane, Schlappi et al. demonstrated that as few as 25 copies of a 
target DNA molecule from 50 mL of buffer could be enriched via filtration at a 
sample processing rate of 1 mL per minute, and that PCR could be performed 
directly on nylon membranes without elution85. 
A POC test for TV detection with improved sensitivity, suitable for low-
resource settings and compatible with non-invasive urine specimens remains an 
unmet need86. The purpose of this study was to assess the feasibility of using 
electrostatic capture to rapidly enrich DNA from large-volume urine samples in 
order to improve downstream TV detection when coupled with an isothermal 
NAAT and a colorimetric LFIA readout. Using off-the-shelf parts, I developed a 
syringe-based prototype to enrich DNA from urine on a chitosan-functionalized 
filter which can be used as template for a tHDA TV assay. I incorporated an 
internal amplification control into our tHDA assay to ensure that potential 
inhibitors from the urine sample matrix do not result in false negative test results. 
I evaluated our tHDA assay and rapid DNA enrichment strategy with simulated 
and clinical urine samples and provide a demonstration of DNA enrichment from 





3.2 Materials and Methods 
Chitosan 
Chitosan (high purity, non-animal derived, 99% degree of deacetylation, 
average molecular weight 100k kDa) was purchased from Sigma Aldrich (Cat. 
No. 9003444) and dissolved to a concentration of 0.5% (w/v) in 0.1 M acetic acid 
solution and stored at 4°C. Chitosan is an amino polysaccharide derived from 
chitin which contains a single primary amine functional group per monomer. As 
previously mentioned, it is this amine group which endows chitosan with charge 
switching properties; at a slightly acidic pH (<6.3) this amine group becomes 
protonated and assumes a partial positive charge. At neutral pH, the amine 
group maintains a neutral charge. 
Fluorescent labeling of chitosan with FITC 
To facilitate direct and specific visual detection of chitosan deposited on 
substrates, fluorescein isothiocyanate (FITC) was covalently attached to the 
chitosan polymer at the primary amine (Figure 14). FITC was purchased from 
Fisher Scientific (MilliporeSigma Cat No. 343211GM) as a dried reagent. 
Chitosan was first dissolved in acetic acid [0.1 M] at a 1% (w/v) concentration 
and FITC was dissolved in 99.8% methanol (Sigma-Aldrich, ACS reagent grade) 
to a final concentration of 1 mg/mL. Equal volumes of chitosan and FITC 
solutions were mixed and incubated at room temperature for 1 hour to allow for 




Figure 14: Fluorescent labeling of chitosan with FITC 
 
chitosan was precipitated via the addition of 1 mL of 1 M NaOH per 25 mL of 
chitosan solution. Chitosan was pelleted by centrifugation at 1600 rcf for 2 
minutes and the supernatant containing unreacted FITC was discarded. To 
remove additional unreacted FITC, a wash of 30 mL of 0.2 M NaOH was then 
added to the chitosan pellet and the solution was vortexed for 5 seconds to 
resuspend the pellet. The sample was centrifuged as before and the supernatant 
was removed. This process was repeated 4 additional times with 0.2 M NaOH 
and 5 times with deionized water until no color was visually detected in the 
washing solutions. The fluorescein-labeled chitosan pellet was then resuspended 
to a final centration of 0.25% in 0.1 M acetic acid and stored at 4°C until use. 
Plasma treatment of Fusion 5 
Fusion 5 (GE Healthcare, Chicago, IL) is a glass-fiber membrane material with 
a proprietary plastic coating, originally intended for use as conjugate release 
membrane material for LFIA devices. Prior studies suggested that DNA capture 




pretreatment of the Fusion 5 material with oxygen plasma prior to incubation in a 
solution of chitosan84. Fusion 5 material was cut into squares with approximately 
0.75 inch sides before an oxygen plasma treatment was applied. Specific 
parameters including flow rate and power were not provided in the primary 
literature, thus a range of plasma treatment conditions were tested. Oxygen 
plasma was applied to 2 pieces of Fusion 5 at a time using a M4L RF Plasma 
System (PVA TePla America, Inc) with varied oxygen flow rates (100, 250, and 
400 SCCM) and applied RF power (100 or 400 W). Additionally, air plasma 
treatment was tested using a Basic Plasma Cleaner (Harrick Plasma, Cat. No. 
PDC-32G) using the high power setting and rarified air. All plasma treatments 
were conducted for 1 minute. 
Deposition of chitosan onto Fusion 5 membranes 
Fusion 5 membranes were prepared for functionalization either by 
pretreatment with plasma (as described in the previous section) or using a simple 
sodium hydroxide (NaOH) wash without pretreatment with plasma. In this second 
protocol, Fusion 5 membranes were cut into 7 x 13 cm sheets and washed in a 
basin containing 30 mL of 0.2 M NaOH under rotation for 5 minutes. The NaOH 
solution was aspirated and the sheets were washed 3 times with 50 mL of DI 
water (under rotation, 5 minutes per wash) before drying under vacuum at 50 °C. 
Once dried, NaOH washed Fusion 5 membranes were stored in zip lock baggies 




FITC-chitosan solution or unlabeled chitosan solution were diluted to a final 
concentration of 0.25% (w/v) in 0.1 M acetic acid solution. 30 mL of chitosan 
solution was poured on top of Fusion 5 sheets in a basin and incubated at room 
temperature under rotation at 100 rpm for 16 hours. Chitosan solution was 
aspirated, and the sheets were washed 3 times with 50 mL of DI water (under 
rotation, 5 minute wash) before drying under vacuum at 50 °C. Chitosan-
functionalized Fusion 5 sheets were then individually stored in sealed plastic 
bags at 4 °C until use. 
Imaging of FITC-chitosan functionalized Fusion 5 
In order to quantify the deposition density of chitosan on the Fusion 5 
substrate via densitometry, chitosan was tagged with fluorescein isothiocyanate 
(FITC). Chitosan was dissolved in acetic acid (0.1 M) to a concentration of 1% 
(w/v). FITC was dissolved in methanol at a concentration of 1 mg/mL. Equal 
volumes of chitosan and FITC solutions were mixed and incubated at room 
temperature for 1 hour to allow for covalent FITC tagging of chitosan. Following 
incubation, FITC-tagged chitosan was precipitated via the addition of 1 mL of 1 M 
NaOH per 25 mL of chitosan solution. Chitosan was pelleted by centrifugation at 
4000 RCF for 2 minutes and the supernatant containing unreacted FITC was 
discarded. To remove additional unreacted FITC, A wash of 30 mL of 0.2 M 
NaOH was then added to the chitosan pellet and the solution was vortexed for 5 
seconds to resuspend the pellet. The sample was centrifuged as before and the 




M NaOH and 5 times with deionized water. The chitosan pellet was then 
resuspended to a final centration of 0.25% in 0.1 M acetic acid.  
FITC-tagged chitosan was used to functionalize a sheet of NaOH treated 
Fusion 5 paper as explained in the Materials and Methods section. 0.5 inch 
diameter samples of Fusion 5 treated with chitosan or FITC-tagged chitosan 
under white light and 488 nm excitation; autofluorescence from the native 
chitosan was found to be negligible. I ruled out the possibility of unintended 
adsorption of FITC onto the Fusion 5 substrate altering the chitosan 
functionalization process using a washout experiment. Four 0.375 inch diameter 
disks of Fusion 5 with varying treatments were used namely: NaOH treatment 
only NaOH treatment, saturated with 200 mg per mL FITC in 0.1 M acetic acid 
and dried FITC-tagged chitosan functionalization. All samples were soaked with 
Tris EDTA buffer (pH 8.0) and imaged with white light and excitation at 488 nm. 
Samples 2 and 4 were placed on a piece of blotting paper, washed with 5 mL of 
methanol by pipette, dried, and soaked with 100 mM Tris before reimaging. FITC 
was readily washed from the Fusion 5 substrate while chitosan-bound FITC was 
retained by the membrane indicating that adsorption of FITC-tagged chitosan 
onto the Fusion 5 substrate was mediated by the chitosan rather than FITC. 
To create reference standards, FITC-tagged chitosan was serially diluted 
fourfold from 0.25 – 0.00098% (w/v) in 0.1 M acetic acid. 32 µL aliquots of each 
standard solution as well as a negative control were applied to 3 separate 0.375 




for 2 hours. Standards and a 7 cm x 11 cm piece of FITC-chitosan-functionalized 
Fusion 5 were wetted with Tris EDTA buffer (pH 8.0) and imaged on a VersaDoc 
MP 4000 molecular imager (Bio-Rad, Hercules, CA). Densitometry was 
performed using ImageJ (NIH, Bethesda, MD) and a standard curve was 
generated after background correction. Using this standard curve, chitosan 
deposition density was found to be 45.9 ± 5.70 ng/cm2. 
Design and assembly of DNA capture device 
The main objective of this work was to develop a sample preparation strategy 
that would enable rapid capture and purification of DNA from large volumes of 
urine for downstream detection of pathogen DNA via NAA. I also hypothesized 
that downstream NAAT sensitivity could be improved on a sample concentration 
basis by amplifying DNA that is first locally enriched within a chitosan-
functionalized filter. To keep costs acceptably low, I selected a 4 mm diameter 
chitosan functionalized Fusion 5 filter size, as a filter of this size could be easily 
housed within a PCR tube and submerged in a standard 25 µL tHDA reaction, 
enabling direct amplification of DNA captured within the filter. As a practical 
matter, I hoped to show that this sample preparation strategy could be performed 
in a matter of minutes as rapid sample-to-answer times are considered desirable 
for POCTs generally, and especially in use cases where asymptomatic 
individuals are subject to screening for STIs. Given our selection of a small filter 
to facilitate both high local enrichment of DNA and direct tHDA amplification 




the filter, the sample processing device necessarily had to withstand relatively 
high sample application pressures required to drive sample flow through the filter. 
Over the course of this work, a number of different strategies were examined for 
housing of chitosan functionalized Fusion 5 membranes and interfacing with 
sample volumes loaded into syringes. Ultimately, simple yet effective, low cost 
housings were fabricated using off-the-shelf parts with minor modifications (figure 
15). Briefly, a 2mm-diameter opening was made in a female Luer cap (Cat no. 
EW-30800-12, Cole-Parmer, Vernon Hills, IL) using a biopsy punch. A 4mm-
diameter disk of cellulose paper (GB003, Whatman) was collected with a biopsy 
punch and positioned in the Luer cap. A 4mm-diameter disk of chitosan-
functionalized Fusion 5 was collected and positioned in the Luer fitting against 
the cellulose backing membrane. While the assembly can be held together 
without the cellulose backing membrane, its inclusion was found to be a simple 
method to prevent dislodging of the chitosan-functionalized filter membrane 
during high flow rate sample application. This additional membrane provides 
mechanical stability and is not expected to affect capture efficiency, as it is 






Quantification of DNA capture efficiency by chitosan-functionalized Fusion 
5 material using flow through analysis 
To measure the DNA capture efficiency by the chitosan functionalized Fusion 
5 filter disk, sample containing a known concentration of control DNA was 
passed through the Fusion 5 filter disk using a syringe pump and the 
concentration of the effluent was measured (Figure 16).  
Phage lambda DNA (New England Biolabs, Ipswich, MA) was diluted in either 
50 mM MES buffer (pH 5.0) or 100 mM Tris buffer (pH 8.5) to a final 
concentration of 0.5 ng/μL. 2.5 mL samples were loaded into 5 mL syringes (Cat 
no. 309646, BD, Franklin Lakes, NJ) and chitosan-functionalized filters were 
attached to each syringe. Sample was applied to the filter at 1 mL per minute; 4 
successive 500 μL fractions of flow-through were collected. Samples without 
DNA were included for background subtraction. DNA concentration of the  
Figure 15: DNA capture device diagram. Sample (at pH 5 or lower) is collected in a 
luer lock compatible syringe. Depression of the plunger causes the sample to first 
pass through a 4 mm diameter chitosan-functionalized Fusion 5 filter (1) where DNA 
is trapped electrostatically. The DNA capture filter is supported by cellulose paper 
backing membrane (2) for added rigidity. Both filters fit securely within a luer cap (3) 





Figure 16: Indirect measurement of DNA mass captured on chitosan-functionalized 
Fusion 5 filters can be calculated by measuring the DNA concentration of the effluent 
 
flowthrough was measured in triplicate for each fraction using SYBR Green 
(Invitrogen) staining and a SpectraMax M5 fluorescence reader (Molecular 
Devices) and compared to a standard curve diluted in the appropriate buffer. The 
DNA mass captured on the chitosan functionalized filter was assumed to be 
equivalent to the DNA removed from the flow-through. An asymptotic line of best 
fit was applied to each series of flow-through data. The cellulose backing 
membrane was excluded from the assembly as cellulose binds DNA. 
DNA stocks and clinical samples 
Genomic DNA from TV strain G3 (PRA-98D) was purchased from ATCC 
(Manassas, VA). Control plasmid DNA containing a region of the X. laevis 
genome was propagated using standard culturing methods, extracted using a 




quantification via spectrophotometry/ De-identified, discarded urine samples from 
patients with suspected TV infection were collected at clinics affiliated with either 
Beth Israel Deaconess Medical Center or Boston Children’s Hospital with 
institutional review board approval.  Studies were approved by the institutional 
review board at each respective hospital. Samples were originally collected using 
Aptima Urine Specimen Transport Tubes (Hologic, Marlborough, MA) that 
contain a buffer that lyses the sample and stabilizes nucleic acids. The use of 
this transport buffer for the sample bank necessitated an extra step to remove 
inhibitors (detailed below); this step would not be necessary when using 
fresh/neat urine samples. The presence or absence of TV in each sample was 
determined using the clinical testing result (positive/negative) from the Aptima TV 
Assay performed on the Panther System (Hologic), after which samples were 
stored at -80°C in the original containers. Upon receipt, samples were thawed at 
room temperature, split into 500 µL aliquots, and returned to -80°C. 
Clinical sample DNA extraction for TV quantification by qPCR 
I determined the TV load for each specimen using qPCR. All PCR and tHDA 
primers used in this study are listed in Table 7. 500 µL sample aliquots were 
thawed and incubated in a 50°C water bath until no cryoprecipitate was visible. 
The pre-lysed urinary sediment was pelleted by centrifugation at 3k RCF for 15 
minutes at room temperature and the supernatant was transferred to a new tube. 
106 copies of a linearized plasmid containing a DNA sequence from the X. laevis 




sulfate (SDS) from the collection buffer was precipitated by the addition of 500 µL 
of 3M sodium acetate (pH 5.0). Precipitate was pelleted by centrifugation at 21k 
RCF for 5 minutes and cleared supernatant was transferred to a new tube; 
residual precipitate was pelleted by re-centrifugation. Buffer exchange was 
performed using a Microcon-30kDa Centrifugal Filter Unit (Millipore Sigma, 
Burlington, MA): 250 µL of cleared supernatant was applied to a spin column and 
centrifuged at 14k RCF for 10 minutes or until the sample volume passed 
completely through the filter with DNA retained on the filter membrane. Samples 
were washed 4 times with 250 µL of EB before inversion and elution into 100 µL 
of EB. Samples were stored at -20°C until qPCR quantification. 
X. laevis TaqMan PCR assay 
25 µL PCR reactions containing 5 µL of extracted nucleic acid were prepared 
with 0.625 units of SureStart Taq polymerase (Agilent, Santa Clara, CA), 3mM 
Table 7: PCR and tHDA primers for TV and X. Laevis targets 
 
TV qPCR   
 TV Forward 5'-AAAACCTTCTGCCAAGTTGTCTGACA-3' 
 TV Reverse 5'-ACTTCTGGAGCATATTGGTATCCGACA-3' 
TV tHDA   
 TV Forward* 5'-AAAACCTTCTGCCAAGTTGTCTGACA-3' 
 TV Reverse* 5'-/5Biosg/ACTTCTGGAGCATATTGGTATCCGACA-3' 
 TV FAM Probe 5'-AGAAAGGTTGCAATGGAATTTTCT/36-FAM/-3' 
 TVIC DIG Probe 5'-TATTTGAAGACTCTACTG/3Dig_N/-3' 
X. laevis qPCR   
 XL Forward 5'-GCAAAACGGCTTGCTTGAATAAGCTGCT-3' 
 XL Reverse 5'-TGCAGTTGATGTAAACCGTCTTGCATTG-3' 
 XL Probe 5'-/5HEX/CTTGAGGTCATCCTTGCTCTCCTGC/3IABKFQ/-3' 




MgCl2, 800µM dNTPs, 200 µM forward primer, 200 µM reverse primer, and 200 
µM TaqMan probe), 1.5 nM ROX passive reference dye, and 1X final 
concentration of the manufacturer-supplied buffer. Primer and probe sequences 
are provided in table 7. Samples were heated to 50°C for 2 minutes followed by 
95°C for 10 minutes to activate the polymerase and then 35 PCR cycles were 
performed, each consisting of 95°C for 15 s, 67°C for 60 s, and 72°C for 60 s. A 
standard curve was generated using tenfold dilutions of the X. laevis control 
plasmid from 106 to 102 copies. 
TV qPCR assay 
25 µL PCR reactions containing 5 µL of sample were prepared with 0.625 
units of SureStart Taq polymerase (Agilent), 3mM MgCl2, 800µM dNTPs, 200 µM 
TV forward primer, 200 µM TV reverse primer, 250 nM EvaGreen (Biotium, 
Hayward, CA), 1.5 nM ROX passive reference dye, and 1X manufacturer-
supplied buffer. Primer sequences are provided in table 7. Reactions were 
heated to 50°C for 2 minutes followed by 95°C for 10 minutes to activate the 
polymerase. 40 PCR cycles were performed, each consisting of 95°C for 15 s, 
62°C for 30 s, and 72°C for 60 s. A melting curve was generated by heating 
samples from 72°C to 95°C to ensure specificity of the PCR product.  
To determine the limit of detection (LOD) and the limit of quantification (LOQ) 
of the TV qPCR assay, TV control plasmid was serially diluted twofold from 128 




were performed at each concentration. Real-time data were collected and gel 
electrophoresis was performed to confirm presence of the expected TV PCR 
product; replicates which displayed amplification but were found to only contain 
nonspecific PCR artifacts (primer-dimers) were assumed to be TV negative. 
These results were used to calculate the LOD and the LOQ as described in the 
statistical analysis section. Clinical samples were quantified by qPCR in triplicate 
and were considered TV positive if at least 2 of 3 replicates resulted in TV 
detection. Clinical sample loads were calculated taking into account extraction 
efficiency and dilution factor. Samples were assumed to be 50% urine by volume, 
however actual values could range from 42.8 – 55.6% as per the collection 
protocol; thus, clinical loads are 85.7 – 111% of the reported value. 
TV/TVIC tDHA assay 
Formulation of the TV/TVIC tHDA is identical to the assay described in chapter 
2. To detect DNA captured using our device directly, 4 mm diameter chitosan 
functionalized Fusion 5 disks were positioned within wells of a 96 well PCR plate 
and 25 µL of tHDA mastermix was pipetted into wells containing filter disks prior 
to incubation in a thermocycler. The presence of chitosan-functionalized paper in 
the reaction did not result in tHDA inhibition. However, relative to the same 
amount of template present in a well-mixed tHDA reaction solution, amplification 
of DNA template captured on paper was found to be delayed. In order to 
maintain sensitive detection of TV DNA when captured on chitosan functionalized 




hold was added to the end of the run. 
Chitosan DNA polyplex formation assay 
In order to examine effects of various buffer systems on the electrostatic 
interactions between DNA and chitosan, a simple qualitative assay was 
developed. It is known that in solution, mixed population of cationic and anionic 
polymers can spontaneously form polyplexes87. Under lightly acidic conditions 
chitosan is expected to maintain a net positive charge; I reasoned that chitosan 
and DNA should form a polyplex due to their difference in charge. To test this, 
salmon sperm DNA (Thermo Fisher, cat no. 15632011) was diluted to a final 
concentration of 500 ng/uL alongside 0.01% (w/v) chitosan. When this reaction 
was performed in MES (50 mM, pH 5.0) formation of a white pellet was observed 
following centrifugation at 15,000 RCF. Treating the presence or absence of this 
pellet as a readout enabled a cursory examination of various additives and buffer 
systems on the desired electrostatic interaction between chitosan and DNA. 
Statistical analysis 
LOD for all assays were determined by probit regression using MATLAB; 
reported LOD values are the lowest amount of TV DNA at which the probit model 
predicts 95% positive detection. LOQ for qPCR assays was defined as the lowest 
concentration for which the coefficient of variance (standard deviation divided by 
the mean) of measured template quantities remained below 35%, following the 




of our test using clinical samples determined to be either positive or negative for 
TV using the Aptima TV Assay as the reference method. Samples were 
considered positive for TV by our test if at least 2 out of 3 replicates resulted in 
LFIA detection of the TV product. 
Lateral flow immunoassay detection of tHDA products 
Biotinylated single-stranded tHDA products (both TV and TVIC) are formed 
when excess biotinylated reverse primer is used in a tHDA reaction. Biotinylated 
tHDA product can bind in a sequence specific manner to either the fluorescein 
(FAM) tagged TV probe, or to the digoxigenin (DIG) tagged TVIC probe. While 
this scheme worked as expected in analytical samples, I found that for chitosan-
based capture it was necessary to include a final 1-minute 95°C step. Post 
amplification melting of tHDA products via thermal denaturation allowed for 
integration of the antigen-tagged oligonucleotide probe sequences and enhanced 
LFIA sensitivity. tHDA product was run on commercial LFIAs (D003-05, USTAR 
Biotechnologies, Hangzhou, China) which contain anti-FAM and anti-DIG test 
lines in addition to an anti-streptavidin control line. 4 µL of tHDA product is 
applied to the LFIA and 2 drops of running buffer are applied to drive wicking flow 
through the LFIA strip. The biotin-tagged tHDA products bind to streptavidin-
coated gold nanoparticles and then pass over anti-FAM and anti-DIG antibody 
test lines where they can bind specifically and accumulate. Any unbound gold 
nanoparticles are then captured on an anti-streptavidin antibody control line. 




test: appearance of the anti-FAM test line indicates a TV positive result; 
appearance of only the anti-DIG line indicates a valid TV negative result; 
absence of both test lines indicates an invalid test in which tHDA did not occur 
appropriately. LFIA strips were imaged (DS-Ri2, Nikon, Minato, Tokyo, Japan) 
and test line intensities were measured using ImageJ (NIH, Bethesda, MD); TV 
test lines were considered positive if their intensity was at least 10% of the TVIC 
and control lines combined. 
Electrostatic capture and tHDA detection of TV DNA 
All sample processing with chitosan-functionalized DNA capture filters was 
performed at a flow rate of 20 mL per minute using a syringe pump; sample 
matrices, volumes, and handling varied across experiments. Following sample 
application, the chitosan functionalized disk was removed from the assembly, 
placed on a piece of cellulose blotting paper (GB003, Whatman), and washed 
with 200 µL of 50 mM MES (pH 5.0). 5 µL of EB containing 105 copies of the 
TVIC plasmid were then added to the disk by pipette. DNA capture filters were 
placed in wells of a 96-well PCR plate and real-time tHDA was performed, 
followed by LFIA testing and polyacrylamide gel electrophoresis.  
Analytical limit of detection samples 
5 mL of 50 mM MES buffer containing either 10, 1, 0.1, 0.01, or 0 TV genomic 
equivalents per mL was loaded into a 5 mL syringe. A DNA capture filter was 




at a rate of 20 mL per minute, after which the filter was removed. 5 replicates 
were performed for each DNA template concentration on 2 separate days.  
DNA capture from clinical samples 
500 µL of clinical sample was mixed with 500 µL of 3M sodium acetate (pH 
5.0) and mixed by vortexing, both to precipitate SDS from the storage buffer and 
to reduce sample pH for electrostatic capture on chitosan-functionalized filters. 
Precipitated SDS was pelleted by centrifugation at 21k RCF for 5 minutes and 
cleared supernatant was transferred to a new tube and recentrifuged to pellet 
any residual precipitate. The sample was then loaded into a 5 mL syringe (Cat 
no. 309646, BD) and the entire sample volume was applied to a chitosan-
functionalized filter at a rate of 20 mL per minute using a syringe pump. A single 
aliquot from each clinical sample was tested on 3 separate days. 
DNA capture from large-volume urine samples 
Pooled human urine was purchased from Innovative Research (Novi, MI) and 
frozen at -20°C until use. After thawing in a 50°C water bath, urinary 
cryoprecipitates were pelleted by centrifugation at 650 RCF for 5 minutes and the 
cleared supernatant was collected and mixed with 1 volume of 50 mM MES (pH 
5.0) to adjust pH for DNA capture by the chitosan-functionalized filter. TV DNA 
was added to 48 mL of pH-adjusted urine to a final concentration of 43.2 fg (0.25 
TV genome mass equivalents) per mL and loaded into 60 mL syringes (Cat no. 




of sample were applied to 3 separate chitosan-functionalized DNA capture filters; 
controls consisting of the sample matrix without TV DNA were also tested. 5 
replicates were performed on 2 separate days. 
3.3 Results and Discussion 
Functionalization of Fusion 5 with chitosan 
 The protocol for functionalization of Fusion 5 membrane with chitosan was 
adopted from the work of Gan et al. where the authors demonstrated that nucleic 
acids could be captured via electrostatic interactions with chitosan-functionalized 
Fusion 5 membranes cold be amplified via PCR84. In this study, the authors 
functionalized Fusion 5 membranes with chitosan by first “activating” the Fusion 
5 with oxygen plasma for 1 minute before submerging the membranes into a 
solution of chitosan (0.05% (w/v) in 0.1% acetic acid, pH 6.0) overnight 
incubation under agitation with a tube roller. The membranes were then washed 
in deionized water (DI water) 3 times before being dried at 50°C in a vacuum 
oven. This treatment protocol was based on the theory that oxygen plasma 
treatment should generate uniform net negative charges on the surface of the 
glass fibers of the Fusion 5 membrane which should then in turn facilitate 
adsorption of the positively charged chitosan polymers via electrostatic 
interactions84. In support of this theory, the authors found that DNA capture by 
chitosan functionalized Fusion 5 was nearly 100% when Fusion 5 membranes 




the capture membranes in a lightly acidic (pH 5) carrier solution (figure 17). 
The authors infer that inclusion of the oxygen plasma treatment improves 
adsorption of chitosan onto the Fusion 5 membrane and in turn, that this 
treatment results in an increased DNA capture efficiency. In their studies, DNA 
capture efficiency was calculated via quantitative PCR (qPCR); briefly a known 
mass of either genomic weight K562 DNA or phage λ DNA is passed through 3 
mm diameter discs of chitosan-functionalized Fusion 5 before membranes and 
subsequently, qPCR is performed using DNA captured on the filter discs as 
template without elution. Comparison to a standard curve is then used to 
ascertain the total template mass present in a given sample and the authors then 
back calculate the apparent capture efficiency. 
At the outset of this work, I wanted to verify that chitosan adheres to the 
Fusion 5 membrane substrate via direct observation rather than relying on 
Figure 17: Reported DNA capture efficiencies by chitosan functionalized Fusion 5, 




functional measurements, such as DNA capture efficiency. I elected to use FITC-
labeled chitosan in order to easily visualize chitosan deposited onto Fusion 5 
membranes. I first verified that only Fusion 5 functionalized with FITC-labeled 
chitosan generated fluorescence under excitation under blue (488 nm) light 
(figure 18). 
Given that no native autofluorescence in the examined excitation and emission 
spectra were observed, and that FITC-labeled chitosan membranes were easily 
observed by fluorescent imaging I wanted to next examine if the presence of 
FITC was likely to alter the hybridization of chitosan to the Fusion 5 substrate. To 
accomplish this, I performed a washout experiment to examine whether FITC 
could hybridize to Fusion 5 independently of chitosan. Briefly, NaOH washed 
fusion 5 was treated either with FITC, FITC-chitosan, or buffer and a 5 mL 
methanol wash was applied to the FITC and FITC-chitosan conditions. White 
light and fluorescence images were collected before and after the methanol 
wash. While the methanol wash was able to remove free FITC from the Fusion 5 
Figure 18: Visualization of FITC labeled chitosan on Fusion 5. Under white light, 
Fusion 5 material functionalized with chitosan and FITC-labeled chitosan appear 
nearly identical. Under excitation with light at 488 nm, only the Fusion 5 
functionalized with FITC-labeled chitosan exhibits fluorescence indicating that any 




substrate below detectible levels, the FITC-chitosan functionalized membrane 
retained detectible fluorescence after the methanol wash suggesting that 
hybridization of FITC-chitosan to the Fusion 5 material is mediated by presence 
of chitosan polymer rather than the FITC moiety (Figure 19). 
Figure 19: Fusion 5 hybridizes to chitosan but not FITC. Fusion 5 disk were treated 
with (1) NaOH only (2) FITC to saturation (3 & 4) FITC-tagged chitosan. All samples 
were first imaged with white light and excitation at 488 nm. Samples 3 and 4 were 
placed on a piece of blotting paper, washed with 5 mL of methanol and then 
reimaged. FITC was readily washed from the Fusion 5 substrate (3) while chitosan-




Given the above findings, I went on to examine what effects various oxygen 
plasma pretreatments on Fusion 5 had on subsequent chitosan deposition 
density using FITC-labeled chitosan for direct observation (Figure 20). 
Figure 20: Both oxygen and air plasma pretreatment of Fusion 5 material decrease 




Contrary to prior data that suggested that oxygen plasma treatment may 
increase the deposition of chitosan onto the Fusion 5 material, my results 
indicated that the oxygen plasma pretreatment of Fusion 5 decreases 
subsequent chitosan density. Given this finding, I did not apply oxygen plasma 
pretreatment of the Fusion 5 material prior to functionalization with chitosan. 
Quantification of chitosan density on functionalized Fusion 5 
Densitometry analysis of Fusion 5 disks containing known masses of FITC-
chitosan enabled the generation of a standard curve which was used to assess 
surface density of chitosan applied by my functionalization protocol (figure 21). 
On average, chitosan deposition density was found to be 45.9 ± 5.70 ng/cm2 with 
some minor heterogeneity in surface density observed. 
  




Capture of DNA by chitosan-functionalized Fusion 5 membranes 
Results from the Gan et al. work suggested that DNA capture efficiency (as 
measured by qPCR performed directly on DNA captured on chitosan-
functionalized Fusion 5) could exceed 95% (Figure 16). Before proceeding 
further, I wanted to examine if I could replicate this capture efficiency using 
Fusion 5 material functionalized with chitosan absent an oxygen plasma 
pretreatment. I measured the DNA capture efficiency of Fusion 5 with and 
without chitosan modification and with and without a NaOH prewash of the 
Fusion 5 material prior to chitosan functionalization in a 50 mM MES (pH 5.0) 
carrier buffer. Additionally, DNA capture efficiency of NaOH washed and chitosan 
functionalized Fusion 5 capture membranes was examined in 100 mM Tris buffer 
(pH 8.5) in which electrostatic capture was not expected to occur due to lack of 
protonation of the chitosan polymer (Figure 22). 
Even in the absence of oxygen plasma pretreament, 96.7% DNA capture 
efficiency was observed on chitosan functionalized Fusion 5 with a simple NaOH 
was pretreament when 250 ng of DNA was applied. Declining capture efficiency 
was observed in subsequent fractions, presumably due to saturation of the 
chitosan-functionalized filter. The calculated binding capacity of our filter is 
approximately 490 ng of DNA. DNA capture was pH dependent; when alkaline 
Tris buffer (pH 8.5) was used, binding capacity of the membranes was 30 ng of 




entanglement of nucleic acids within the fibrous filter membrane and has been 
observed by other groups24. In the absence of chitosan functionalization, no 
appreciable DNA capture was observed by untreated Fusion 5 or Fusion 5 
washed with NaOH. DNA capture was still observed when Fusion 5 was treated 
with chitosan without first washing with NaOH; however, total DNA binding 
capacity decreased to 360 ng. This may be due to increaseddeposition of 
chitosan on the NaOH washed filter membranes relative to the unwashed 
membranes. 
 
Figure 22: Lambda DNA capture on chitosan-functionalized filters was found to be 
pH dependent as expected. With NaOH washing, chitosan functionalization, and an 




Preincubation with of captured DNA in elution buffer prior to amplification 
decreases tHDA threshold times 
I next wanted to see if a factor other than DNA capture efficiency could explain 
the discrepancy between my observed high DNA capture efficiency absent 
oxygen plasma pretreatment and results from Gan et al. which suggested that 
this was necessary. I hypothesized that, while DNA capture by the chitosan 
functionalized filter may occur with high efficiency, it was possible that captured 
DNA was not readily available for participation in subsequent NAA reactions 
which could result in an decrease in perceived DNA capture efficiency. I 
reasoned that including a preincubation step, where captured DNA could diffuse 
from the filter into the bulk reaction mixture may increase apparent DNA 
concentration by quantitative NAA methods. I initially attempted to perform this 
study using qPCR, but was unable to successfully replicate reliable detection of 
real time PCR amplification when chitosan functionalized filters were present in 
the reaction (data not shown). However, real time tHDA appeared to tolerate 
presence of this chitosan functionalized Fusion 5 during the reaction with little 
optimization and thus this was selected for further study. As described in the 
methods, I applied a fixed copy number of TV control plasmids onto chitosan 
functionalized filters, and subjected the samples to one of 2 treatments, a 
preincubation in 1X tHDA buffer (pH 8.0) at 65°C to promote elution or no 




I observed that, inclusion of a preincubation step decreased tHDA threshold 
times by 3.82 minutes on average. For the conditions tested, a 10-fold increase 
in template concentration corresponded to a decrease in threshold time of 3.05 
minutes. Thus, inclusion of the preincubation step resulted in a roughly 18-fold 
increase in apparent captured DNA concentration relative to a comparable 
sample without a preincubation elution step. Still, even this additional 30 minute, 
Figure 23: Preincubation elution of captured DNA decreases tHDA threshold time 
and increases apparent template concentration via quantitative tHDA. A) 
Experimental design B) Comparison in tHDA threshold times for equivalent TV 
template loads added in an aqueous solution to the mastermix, captured on chitosan-
functionalized filters with a preincubation elution step, or without elution C) tHDA 






a 5.82 difference in threshold time was observed between eluted, captured DNA 
and an equivalent amount of template added directly to the mastermix; this 
corresponds to an 81-fold difference in apparent concentration by quantitative 
tHDA. These results illustrate that when using quantitative NAA methods for 
assessing DNA capture efficiency, availability of captured DNA for participation in 
the amplification reaction must be considered when interpreting results. 
Taken collectively, I conclude that oxygen plasma treatment of Fusion 5 does 
not in fact increase absorption of chitosan, but rather results in a lower deposition 
concentration of chitosan onto the Fusion 5 membrane. Anecdotally, I observed 
that oxygen plasma treated pieces of Fusion 5 were lower in rigidity than 
comparable untreated pieces of Fusion 5. Though further study is needed, it is 
possible that DNA captured on oxygen plasma treated chitosan-functionalized 
Fusion 5 is more readily available for amplification than DNA captured on similar 
substrates without plasma treatment. Possibly underlying mechanisms are 
differing degrees of entanglement of captured DNA with the substrates. As a 
practical matter, if direct amplification of captured DNA template on chitosan-
functionalized membranes is desired for use in a POCT scheme, increased 
availability of template for amplification is desirable as this can clearly reduce the 




Analytical limit of detection characterization of captured DNA 
 Despite the limitations outlined in the previous section, detection of TV DNA 
captured electrostatically on chitosan-functionalized Fusion 5 via direct tHDA and 
LFIA was demonstrated to be a viable diagnostic strategy. To assess the 
analytical LOD of the TV tHDA assay coupled with our electrostatic DNA capture 
system, titrated amounts of genomic TV DNA in 1 mL of MES were subjected to 
capture by chitosan-functionalized Fusion 5 and subsequent direct amplification 
via tHDA. Results demonstrated that as few as 6.92 genomic equivalents of TV 
DNA could be reliably detected using this sample processing strategy (figure 24). 
Compared to the LOD for the TV tHDA assay (found to be 0.2 TV genome mass 
equivalents, see figure 12), this LOD for captured DNA presented a roughly 35-
fold decrease in sensitivity on a DNA mass basis. While this decrease in 
Figure 24: Limit of detection for TV genomic DNA captured from 1 mL of MES is 6.92 
genomic equivalents of TV DNA. Dotted lines indicate the 95% confidence interval of 




sensitivity is undesirable, sensitivity was still quite good requiring fewer than 10 
organisms for detection. Additionally, our electrostatic DNA capture strategy has 
the added advantage of being able to rapidly process many mL of sample. Thus, 
if enrichment of TV DNA could be achieved by processing large volumes of 
sample, I reasoned that effective sensitivity of the assay on a concentration basis 
might be improved. 
Sensitivity is improved by increasing input sample volume 
To test our hypothesis that increasing input sample volumes would increase 
assay sensitivity on a sample concentration basis, mock samples consisting of 
50% urine buffered with MES [25 mM final] were spiked with genomic TV DNA at 
a concentration of 0.25 TV genomic mass equivalents per mL and increasing 
volumes of sample were processed. I observed that increasing the amount of 
sample volume processed by our electrostatic DNA capture device did indeed 
increase assay sensitivity on a sample concentration basis (figure 25). In figure 
23, when 1 mL of input sample was used a concentration of 6.92 genomic 
equivalents of TV DNA per mL were required to achieve a predicted 95% positive 
detection rate. Simply by increasing the amount of input sample volume to 40 
mL, our sample enrichment strategy was able to reliably detect input DNA at a 
concentration of 0.25 genomic mass equivalents per mL, a roughly 28-fold 
increase in sensitivity. In addition to analytical sensitivity of our DNA processing 




variation that exist real samples, thus I tested our device against in clinical urine 
sample discards with known TV status. 
Clinical sample preparation 
As detailed in the methods section, supplied clinical urine samples were 
collected in Aptima Urine Specimen Transport Tubes (Hologic,  Marlborough, 
MA) which contain a buffer, henceforth referred to as Aptima Urine Transport 
Buffer (AUTB), that lyses the sample and stabilizes nucleic acids. Although the 
exact composition of AUTB is proprietary, the supplied safety data sheet 
indicated that the buffer contained sodium dodecyl sulfate (SDS), a common 
detergent and that the pH of the buffer was 8.0. Initial attempts to capture and 
Figure 25: Large volume processing increases test sensitivity. TV DNA was diluted to 
0.25 genomic equivalents/mL in a solution of 50% urine buffered with 25 mM MES. 
DNA from 0.4, 4, and 40 mL aliquots of sample was enriched on our prototype and 
tHDA was performed. Incidence of TV detection increased with sample volume 
demonstrating that DNA enrichment from large sample volumes can increase assay 





amplify DNA with tHDA directly from 50% AUTB failed, and it was found that 
presence of AUTB inhibits tHDA directly at 10% concentration (data not shown). 
It was initially unclear if presence of AUTB decreased electrostatic capture of 
DNA by chitosan-functionalized Fusion 5 membranes, though this was suspected 
due to the high pH of the buffer and possible interference from the negatively 
charged SDS. 
A simple protocol was developed to prepare AUTB containing samples using 
3M sodium acetate (NaOAc) at pH 5.0 for downstream applications. Mock 
samples consisting of 50% AUTB were spiked with salmon sperm DNA at a 
concentration of 500 ng/µL and an equal volume of NaOAc was added and 
mixed by vortexing. Addition of NaOAc resulted in the formation of a white 
precipitate which was then pelleted by centrifugation (Figure 26). DNA 
concentration of the resulting supernatant was then tested by spectrophotometry 
and found to be 231 ng/µL, indicating that 89% retention of input DNA in the 
supernatant. 
To examine the effects of AUTB and AUTB with precipitate removed via 
NaOAc induced precipitation on electrostatic interactions between DNA and 
chitosan, I performed a simple assay to examine if DNA chitosan polyplexes 
could be formed in the presence of either solution. As a positive control buffer 
system, MES (pH 5.0) was used to ensure that chitosan would be maintain a 
positive charge to allow for polyplex formation. AUTB was adjusted to pH 5.0 with 




chitosan was maintained and to prevent precipitation of chitosan which occurs 
natively at lightly alkaline pH. Pellet formation was observed in MES buffer only 
when both DNA and chitosan were present suggesting that the pellet was a 
result of precipitation of DNA chitosan polyplexes rather than either constituent 
independently (Figure 26). Importantly, pellet formation was not observed when 
AUTB (25%, pH 5.0) was used but was observed when supernatant from NaOAc 
treated AUTB (25%, pH 5.2 after NaOAc addition) was used instead. 
Although these qualitative polyplex assay results are not a direct stand-in for 
assessing electrostatic DNA capture efficiency by chitosan functionalized 
membranes, they did make it clear that presence of SDS inhibited the desired 
Figure 26: Sodium acetate treatment effectively precipitates SDS and permits DNA 




electrostatic interactions between DNA and chitosan. 
Given that NaOAc treatment of AUTB containing samples did not result in 
DNA precipitation and enabled electrostatic interactions between DNA and 
chitosan to occur, this sample preparation strategy was used for all clinical 
samples examined in this study. Samples tested for qPCR quantification included 
an additional buffer replacement step using a spin column (see methods), but 
samples tested using our electrostatic DNA capture and direct tHDA protocol 
were tested without any additional steps. Importantly, the need for this NaOAc 
treatment was a consequence of the sample bank used for this study. In practice, 
an orthogonal sample preparation chemistry could be implemented to obviate the 
need for SDS removal from the sample. 
Detection of TV DNA on chitosan-functionalized Fusion 5 is pH dependent 
 Following NaOAc treatment, the pH values of all processed urine samples 
used in this study were measured via litmus test (values included in table 8). pH 
values for all samples fell within the range of 5.0 – 6.5 with variability likely owing 
to both differences in pH in the input urine samples and differences in dilution of 
AUTB due to irregularity in urine sample volume collection. As such, I wanted to 
verify that samples at pH 6.5 were still suitable for electrostatic DNA capture. To 
do so, I examined efficacy of detection of genomic TV DNA [10 genomic mass 
equivalents per mL] with 1 mL sample volumes applied under various pH 




observed in 100% of instances when the sample pH was 5.0 and 89% when the 
pH was 6.5, this dropped to just 22% when the sample pH was increased to 8.5. 
Given the relatively high detection frequency even at pH 6.5, I moved forward 
with examination of clinical samples processed using NaOAc treatment to both 
precipitate SDS and regulate pH.  
Figure 27: DNA capture at various pH. Samples consisting of 50 mM MES buffer (pH 
5.0), 50 mM MES buffer (pH 6.5), and 100 mM Tris buffer (pH 8.5) were prepared 
with a final concentration of TV DNA of either 10 or 0 genomic equivalents per mL. 1 
mL of each sample was processed on our prototype before amplification with tHDA. I 
observed that TV DNA was consistently detected by our method when the carrier pH 




High clinical sensitivity and specificity was observed 
I used this sample bank to characterize the clinical sensitivity and specificity of 
our sample processing device and tHDA assay. Successful LFIA detection of TV 
and/or TVIC occurred in 100% of the samples tested, confirming that tHDA 
occurred in all 62 clinical samples (33 TV negative and 29 TV positive) that were 
examined. Relative to the gold standard Aptima TV Assay, this assay achieved 
96.6% sensitivity and 100% specificity.  
In addition to providing clinical validation of the sample preparation method 
developed in this chapter, to our knowledge, this is the first reported dataset on 
TV parasite loads in urine samples. Our assay failed to detect TV in a subset of 
samples with low parasite loads as measured by qPCR; specific LFIA results are 
listed in table 8. The TV qPCR assay was found to have a LOD of 9.26 copies of 
the measurand sequence (as mentioned in the methods, I estimate that each TV 
genomic mass equivalent of DNA contains 2250 copies of this sequence), 
corresponding to 0.004 TV DNA genomic mass equivalents (figure 28a). The limit 
of quantification was found to be 16 copies of the measurand sequence or 0.007 








Table 8: TV loads and detection frequency of clinical urine samples 
 
 
Aptima TV Assay 
Result 
ID # Sex pH 
TV LFS Detection  
(% Correlation) 
TV load per 500 µL 
Sample 
TV Negative 1 F 6.0 –/–/– (100%) N.D 
 2 F 5.5 –/–/– (100%) N.D 
 3 F 5.5 –/–/– (100%) N.D. 
 4 F 5.5 –/–/– (100%) N.D. 
 5 F 5.5 –/–/– (100%) N.D. 
 6 F 5.5 –/–/– (100%) N.D. 
 7 F 5.5 –/–/– (100%) N.D. 
 8 F 5.5 –/–/– (100%) N.D. 
 9 F 5.5 –/–/– (100%) N.D. 
 10 F 5.5 –/–/– (100%) N.D. 
 11 F 5.5 –/–/– (100%) N.D. 
 12 M 5.5 –/–/– (100%) Below LOQ 
 13 F 5.0 –/–/– (100%) N.D. 
 14 F 5.0 –/–/– (100%) N.D. 
 15 F 5.0 –/–/– (100%) N.D. 
 16 F 5.0 –/–/– (100%) N.D. 
 17 F 5.0 –/–/– (100%) N.D. 
 18 M 5.0 –/–/– (100%) N.D 
 19 F 5.0 –/–/– (100%) N.D. 
 20 F 5.0 –/–/– (100%) N.D. 
 21 F 5.0 –/–/– (100%) N.D. 
 22 F 5.0 –/–/– (100%) N.D. 
 23 F 5.0 –/–/– (100%) N.D. 
 24 F 5.0 –/–/– (100%) N.D. 
 25 M 5.0 –/–/– (100%) N.D. 
 26 F 5.0 –/–/– (100%) N.D. 
 27 F 5.0 –/–/– (100%) N.D. 
 28 F 5.0 –/–/– (100%) N.D. 
 29 F 5.0 +/–/– (67%) N.D. 
 30 F 5.0 –/–/– (100%) Below LOQ 
 31 F 5.5 –/–/– (100%) N.D. 
 32 F 5.5 –/–/– (100%) N.D. 
 33 F 5.0 –/–/– (100%) N.D. 
       
TV Positive 1 F 5.0 +/+/+ (100%) 3.03*101 ± 1.95*100 
 2 F 6.0 +/+/+ (100%) 1.33*10
4 ± 9.47*102 
 3 F 6.0 +/+/+ (100%) 1.26*10
2 ± 5.74*100 
 4 F 5.5 +/+/+ (100%) 2.48*10
2 ± 3.56*100 
 5 F 6.0 +/+/+ (100%) 1.64*10
5 ± 6.34*103 
 6 F 6.0 +/+/+ (100%) 1.18*10
3 ± 4.41*101 
 7 F 6.0 +/+/+ (100%) 4.52*10
1 ± 6.72*100 
 8 F 6.5 +/+/+ (100%) 1.62*10







Aptima TV Assay 
Result 
ID # Sex pH 
TV LFS Detection 
(% Correlation) 
TV Load per 500 µL Sample 
TV Positive 9 F 5.5 –/–/– (0%) N.D. 
 10 F 6.5 +/+/+ (100%) 4.79*103 ± 1.57*102 
 11 F 6.5 –/+/+ (67%) Below LOQ 
 12 F 6.5 +/+/+ (100%) 2.02*101 ± 1.43*101 
 13 F 5.5 +/+/+ (100%) 6.71*101 ± 3.26*100 
 14 F 5.5 +/+/+ (100%) 1.19*101 ± 7.67*10-1 
 15 F 5.5 +/+/+ (100%) 1.08*101 ± 2.98*10-1 
 16 F 5.0 +/+/+ (100%) 1.80*103 ± 6.72*101 
 17 F 5.0 +/+/+ (100%) 5.07*101 ± 4.18*100 
 18 F 5.5 +/+/+ (100%) 7.68*100 ± 1.05*100 
 19 F 5.5 +/+/+ (100%) 1.47*101 ± 3.41*100 
 20 F 5.5 +/+/+ (100%) 4.12*100 ± 5.88*10-1 
 21 F 6.5 +/+/+ (100%) 5.14*100 ± 4.19*10-1 
 22 M 6.5 +/+/+ (100%) 7.51*101 ± 1.51*100 
 23 F 5.5 +/+/+ (100%) Undetermined 
 24 F 5.5 +/+/+ (100%) 7.76*101 ± 4.19*100 
 25 F 5.0 +/+/+ (100%) 7.81*102 ± 9.01*100 
 26 F 5.0 +/+/+ (100%) Below LOQ 
 27 F 5.0 +/+/+ (100%) Below LOQ 
 28 F 5.0 +/+/+ (100%) 7.98*101 ± 9.52*10-1 
 29 F 5.0 +/+/+ (100%) 4.63*102 ± 5.04*100 
 TV LFS Detection: ‘+’ indicates LFIA detection of the TV with or without TVIC detection, ‘–‘ 
indicates TVIC LFIA detection of TVIC without TV detection. TV Load: “Below LOQ” 
indicates positive detection of TV DNA by qPCR, but at a concentration below the limit of 
quantification of our assay; “N.D.” indicates that TV was not detected by qPCR; 
“Undetermined” indicates unsuccessful amplification of the control X. laevis plasmid due 
to PCR inhibition.  
Table 8 (cont.): TV loads and detection frequency of clinical urine samples 
 
Aptima TV Assay 
Result 
ID # Sex pH 
TV LFS Detection 
(% Correlation) 
TV Load per 500 µL Sample 
TV Positive 9 F 5.5 –/–/– (0%) N.D. 
 10 F 6.5 +/+/+ (100%) 4.79*103 ± 1.57*102 
 11 F 6.5 –/+/+ (67%) Below LOQ 
 12 F 6.5 +/+/+ (100%) 2.02*101 ± 1.4 *101 
 13 F 5.5 +/+/+ (100%) 6.71*101 ± 3.26*100 
 14 F 5.5 +/+/+ (100%) 1.19*101 ± 7.67*10-1 
 15 F 5.5 +/+/+ (100%) 1.08*101 ± 2.98*10-1 
 16 F 5.0 +/+/+ (100%) 1.80*103 ± 6.72*101 
 17 F 5.0 +/+/+ (100%) 5.07*101 ± 4.18*100 
 18 F 5.5 +/+/+ (100%) 7.68*100 ± 1.05*100 
 19 F 5.5 +/+/+ (100%) 1.47*101 ± 3.41*100 
 20 F 5.5 +/+/+ (100%) 4.12*100 ± 5.88*10-1 
 21 F 6.5 +/+/+ (100%) 5.14*100 ± 4.19*10-1 
 22 M 6.5 +/+/+ (100%) 7.51*101 ± 1.51*100 
 23 F 5.5 +/+/+ (100%) Undetermined 
 24 F 5.5 +/+/+ (100%) 7.76*101 ± 4.19*100 
 25 F 5.0 +/+/+ (100%) 7.81*102 ± 9.01*100 
 26 F 5.0 +/+/+ (100%) Below LOQ 
 27 F 5.0 +/+/+ (100%) Below LOQ 
 28 F 5.0 +/+/+ (100%) 7.98*101 ± 9.52*10-1 
 29 F 5.0 +/+/+ (100%) 4.63*102 ± 5.04*100 
 TV LFS Detection: ‘+’ indicates LFIA detection of the TV with or without TVIC detection, ‘–‘ 
indicates TVIC LFIA detection of TVIC without TV detection. TV Load: “Below LOQ” 
indicates positive detection of TV DNA by qPCR, but at a concentration b low the limit of 
quantification of our assay; “N.D.” ndicates that TV was not detected by qPCR; 
“Undetermined” indicates unsuccessful amplification of the control X. laevis plasmid due 





Figure 28: TV qPCR assay characterization (A) Presence or absence of TV qPCR 
product was determined via gel electrophoresis; results were fitted using a probit 
model and the limit of detection was found to be 9.26 copies of control plasmid. (B) 
The limit of quantification for the qPCR assay was defined as the lowest 
concentration at which the coefficient of variance (defined as the standard deviation 
divided by the mean of qPCR predicted copy number) did not exceed 35%; this was 







Here, I demonstrated the feasibility of a method for rapid enrichment of DNA from 
urine samples that is compatible with tHDA detection of TV infection. Our TV 
tHDA assay and rapid urine sample preparation strategy yielded 96.6% 
sensitivity and 100% specificity when testing a bank of 29 TV positive and 33 TV 
negative clinical urine samples. Importantly, no inhibition of our tHDA assay was 
observed from any clinical samples. From 1 mL of buffer, the assay achieved an 
LOD of 6.92 TV genomic equivalents per mL. Using this rapid TV enrichment 
method, I demonstrated reliable detection of TV DNA at a concentration of 0.25 
genomic equivalents per mL (a 28-fold increase in sensitivity), which captures the 
lower bound of expected clinical pathogen loads and is more sensitive than 
current POC detection methods. 





Development of an isothermal, tunable semiquantitative assay 
for HBV viral load monitoring 
4.1 Background 
Structure and function of the liver 
The liver is responsible for a wide array of biochemical and physiological 
activities which support metabolism, immunity, digestion, detoxification, vitamin 
storage in addition to many other important functions.88 The basic functional unit 
of the liver is known as the lobule; each lobule is hexagonal in structure, with a 
portal triad (consisting of a portal vein, bile duct, and hepatic artery) positioned at 
each corner and an central vein running through center (figure 29). The body of 
each lobule is composed of hepatocytes which carry out different functions based 
on their position within the lobule and the relative perfusion of blood. 
Hepatocytes nearest to the portal triads have high perfusion due to close 
proximity to oxygenated blood; these hepatocytes play key roles in processes 
requiring oxidation including beta-oxidation, gluconeogenesis, bile formation, 
cholesterol formation, and amino acid catabolism.88 Hepatocytes nearest to the 
interlobular vein have the lowest perfusion and play key roles in detoxification, 





Chronic liver diseases can result in hepatocellular carcinoma and cirrhosis 
Although their underlying causes and pathologies differ, chronic liver diseases 
(CDLs) disrupt normal liver function at the cellular level by deteriorating 
hepatocytes and at the tissue level by distorting lobular architecture.89 Left 
unmitigated, CDLs can cause potentially life-threatening sequelae, the two most 
detrimental being hepatocellular carcinoma (HCC) and cirrhosis. 
Cirrhosis is a condition characterized the excessive formation of scar tissue 




(fibrosis) and nodule formation in the liver. Cirrhosis is a progressive disease 
which can take years to advance from asymptomatic liver inflammation to a state 
of chronic liver failure. In the early stages of CDL induced cirrhosis, the liver 
becomes inflamed and, if left untreated, damaged hepatocellular tissue can be 
replaced with fibrotic scar tissue. As the extent of CDL induced fibrosis 
increases, cirrhosis occurs. During the early stages of cirrhosis, patients do not 
typically present with symptoms as lost hepatic function from damaged regions of 
the liver can be compensated for by healthy liver tissues; this is known as 
compensated cirrhosis. As the degree of fibrosis increases, the liver can no 
longer compensate for this loss of function; this is known as decompensated 
cirrhosis. Following decompensation, both morbidity and mortality associated 
with cirrhosis increases dramatically. While cirrhosis is considered an irreversible 
condition, disease progression can be halted if the cause of underlying CDL is 
treated during the early stages of cirrhosis. 
Important Biomarkers and Tests for Assessing Liver Injury 
There are a variety of important biomarkers and associated laboratory tests 
that are used to assess liver function, or more accurately, to help identify specific 
forms of liver injury. These tests are important for monitoring patients with known 
CLD and can be broadly categorized as being indicative of a hepatocellular injury 
or a cholestatic injury (i.e. injury resulting in the stagnation of bile secretion and 
flow). When damaged, the cell membrane permeability of hepatocytes is 




in the blood is used as proxy for hepatocellular injury. Alanine aminotransferase 
(ALT) is a cytosolic enzyme present at high concentrations hepatocytes; 
observation of ALT blood concentration above of normal reference ranges (0 to 
45 IU/L) is considered the most specific marker for hepatocellular injury. 
Aspartate transaminase (AST), a cytosolic and mitochondrial enzyme, is also 
present at elevated concentrations in hepatocytes can also be used to assess 
hepatocellular injury, but AST is a less specific maker than ALT due to its 
presence in other tissues and organ systems89. Thus, quantification of ALT and 
AST specific activity in serum samples can be used as a measure of liver injury90. 
POC amenable methods have been developed for detection of ALT and AST 
using colorimetric91 and electrochemical92 readouts. While these tests are rapid 
and useful for identifying liver injury, additional methods are needed assess the 
root cause of the liver injury.  
In addition to molecular biomarkers of liver injury, both invasive and 
noninvasive methods can be used to assess the degree of fibrosis in the liver. 
Liver biopsy is an invasive procedure in which liver tissue is sampled for 
histological evaluation. While still not a direct substitute for biopsy, many 
advances have been made in using noninvasive testing modalities, primarily 
magnetic resonance elastography and increasingly ultrasound, to assess liver 
stiffness as a means of detecting advanced fibrosis or cirrhosis. Additionally, 
imaging modalities such as computerized tomography and magnetic resonance 




Ultimately, these molecular and imaging-based assays are well suited for 
assessing the extent of liver injury, but with the exception of biopsy, are not as 
well suited to diagnose a specific underlying condition or conditions causing the 
injury. Accordingly, early detection and continued management of CDLs, either 
through therapy or behavioral intervention, is of the upmost importance to 
prevent the mortality and morbidity associated with advanced decompensated 
cirrhosis and HCC. The management of chronic liver diseases remains a major 
challenge to public health management. 
Prevalence estimates for common liver diseases 
It is estimated that CLDs affect 884 million individuals globally and that 2 
million individual die annually from complications stemming from CDL associated 
cirrhosis and HCC93. The most common CDLs are alcoholic liver disease (ALD), 
nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis 
(NASH), and chronic infection with hepatitis B and/or C virus (HBV & HCV).94 
Hepatitis B Virus burdens on global health 
It is estimated that 2 billion individuals, or 1 in 3 people, have been infected 
with Hepatitis B Virus (HBV). HBV infection can cause acute and chronic disease 
and potentiates risk of morbidity and death due to cirrhosis of the liver and 
hepatocellular cancers95. It is estimated that 600,000 HBV-associated deaths 
occur worldwide each year96; 93% of these deaths are the result of cirrhosis of 




of all HBV-associated deaths result from infections acquired via perinatal 
transmission (21% of all deaths) or before the age of 5 (48% of all deaths)96. 
Thus, early-childhood vaccination programs are priority for HBV mitigation. 
HBV vaccination programs have been effective, but HBV remains a burden 
In 1965, HBsAg was discovered and used to generate an effective vaccine 
against HBV; this vaccine was first made available in 198196. This HBV vaccine 
has been found to be 83% effective against infection and 95% effective in 
preventing chronic infection97. In 1992, the WHO recommended that all countries 
include HBV vaccination into their universal childhood vaccination programs96. 
Although widely distributed, implementation of this HBV vaccine to infants born in 
low and middle income countries was limited due to the associated costs; HBV 
vaccinations cost 3 – 5 more per dose than vaccinations for diphtheria, tetanus, 
and pertussis, polio, and measles96. Starting in 1999, financial support from the 
Global Alliance for Vaccines and Immunization and the Vaccine Fund helped 
accelerate deployment of HBV vaccination programs in low and middle income 
countries98. Although HBV vaccination programs are much more widely available 
today, disparities in coverage still exist regionally99. 
The global prevalence of chronic Hepatitis B Virus (HBV) infection (indicated 
by HBsAg) is estimated to be 3.9% corresponding to 292 million individuals100. 
Large regional variation exists in HBsAg-positive patients ranging from <2% to 




countries bear the majority of the burden HBV infections102. 
Antiretroviral therapy for HBV offers a functional, but not sterilizing cure 
The ultimate goal of treatment is a sterilizing cure, eliminating the infection 
within the patient. This is defined as a sustained absence of HBsAg from serum, 
HBV DNA from both the liver and serum, loss of covalent closed circular DNA 
(cccDNA) and HBV DNA integrated into the genome. This has not yet been 
achieved for HBV103, but has been achieved for hepatitis C virus (HCV) infection. 
Absent a sterilizing cure, the next best target is a functional cure, which is 
indicated by a loss of HBsAg with or without presence of anti-HBs. In this case 
the goal is to improve survival and quality of life by halting disease progression 
and mitigating sequalae of HBV infection, such as HCC, by suppressing 
replication of the virus through the administration of a therapy. However, not all 
individuals with chronic HBV infection require antiviral therapy. Eligibility for 
treatment is determined based on measured levels of serum ALT, presence of 
HBV specific antibodies, presence of HBV surface proteins and, importantly, 
HBV DNA viral load102. 
HBV viral load quantification informs treatment decisions 
 Chronic hepatitis B is a dynamic disease and can transition through different 
clinical phases; individuals under treatment can have widely fluctuating HBV 
DNA viral loads, varying from undetectable to greater than 2,000,000 




genome copies106). For many patients, a low replicative phase is frequently 
encountered during the natural history of chronic HBV infection, during which 
therapy can be avoided. This phase is characterized by HBV viral load < 2,000 
IU/ml107 and was observed in up to 70% of adults after 10 years of chronic 
HBV108. Thus, the WHO guidelines recommend deferring antiretroviral therapy 
for these patients, but initiating serial viral load monitoring every 6-12 months109.  
Quantitative HBV DNA tests are vital to management of patients with chronic 
HBV infection, especially in relation to decisions regarding antiretroviral therapy 
initiation. The American Association for the Study of Liver Disease (AASLD) 
recommends that antiviral therapy be initiated in patients with elevated levels of 
ALT based on their HBeAg status and HBV DNA levels taken together: 
specifically HBeAg-positive patients with viremia >20,000 IU/mL and HBeAg-
negative with viremia >2,000 IU/mL90. In addition to these thresholds, HBV viral 
load can be used to determine the risk of perinatal transmission, which is likely 
for maternal HBV viral load exceeding >200,000 IU/mL90,110,111. These 
recommendations come in part from the recognition that risk of severe liver 
disease, such as HCC for HBV patients correlates with their HBV DNA VL112; 
similarly, recurrence of HCC is more likely after resection for HBV viral loads 
>2,000 IU/mL113 and after liver transplant for HBV viral loads >20,000 IU/mL114. 
HBV reactivation is more likely in cancer patients with higher HBV viral load115. 
Historically, molecular probe-based hybridization assays were used to quantify 




adequate sensitivity103. More recently, NAATs have been implemented to detect 
and quantify HBV DNA from samples; these tests offer high specificity (99%) and 
high sensitivity (>95%) and limits of quantitation on the order of 10 – 20 IU/mL103. 
Widely used tests include Abbott RealTime HBV Viral Load Assay, Biocentric 
HBV Charge Virale, Cepheid Xpert HBV Viral Load, Hologic Panther Aptima HBV 
Quant, the Qiagen HBV PCR Kits CE, Roche cobas® HBV Test, and the 
Siemens VERSANT HBV DNA 1.0 Assay. These commercial tests for 
quantitative HBV viral load testing are expensive (with platform costs as high as 
$150,000, and per test costs from $30 to more than $120)116 and require 
sophisticated instrumentation and equipment, making them better suited for 
centralized testing rather than POCT.  
4.2 SQLA Assay Concept 
Given the importance of repeated VL measurements and that there are many 
viral load thresholds of interest (from 2,000 to over 200,000 IU/mL), a semi-
quantitative HBV DNA viral load test could be employed to aid treatment 
decisions for patients with chronic HBV infection. Recognizing that current HBV 
viral load tests are not suited to POC settings, I sought to develop an assay 
chemistry suitable for non-instrumented HBV viral load quantification suitable for 
POCT. I reasoned that a test with multiple, tunable detection thresholds could be 
tuned to provide semiquantitative HBV viral load data with thresholds 
corresponding to AASLD guidelines (e.g. 2,000 and 20,000 IU/mL). The resulting 




independently tunable quantification. Using this chemistry, standard, off-the-shelf 
LFIA devices can be utilized for naked-eye endpoint readout to infer the input 
concentration of input HBV DNA relative to user defined quantification thresholds 
(figure 30). As I will detail in the following sections, the SQLA assay first utilizes a 
room temperature ligation step to generate 2 species of HBV proxy oligos and a 
subsequent isothermal tHDA step to generate amplicons that are controllably 
detectible by LFIA depending on input HBV DNA concentration. 
 
Ligation generates multiple species of HBV DNA proxy oligonucleotides 
First, input HBV DNA serves as ligation template for upstream and 
downstream probe oligonucleotides (figure 31). The upstream common probe 
and downstream variable probes contain complementary sequences to a 
measurand sequence contained with the HBV polymerase gene at their 5’ and 3’ 
ends respectively. Upon hybridization to the target HBV sequence, 3’ end of the  
Figure 30: Schematic of desired SQLA LFIA readout. Commercial LFIA devices can 
be used to achieve semiquantitative endpoint readout of HBV viral load. A) LFIA 
devices used here contain 2 antibody test lines, anti-FAM and anti-DIG as well as a 
control anti-streptavidin line. B) As input HBV DNA increases in concentration and 
exceeds tunable thresholds, aggregation of gold nanoparticles at the anti-DIG and 






upstream probe and the 5’ phosphorylated end of the downstream probe are 
brought into close proximity forming a ligatable nick. The inclusion of multiple 
species of downstream variable probes enables the formation multiple species of 
ligation products with distinguishable sequences. By design, the 3’ domain of all 
downstream variable probes contain an identical complementary sequence to the 
HBV target sequence. In this initial version of the assay, two species of 
downstream probe have been included in order to ultimately facilitate 
semiquantitative HBV measurement at two quantification thresholds. 
The expected output concentration of any ligation product is dependent can be 






× α𝑙𝑖𝑔𝑎𝑡𝑖𝑜𝑛 × [𝐻𝐵𝑉 𝐷𝑁𝐴𝑖𝑛𝑝𝑢𝑡] 
The first factor is the concentration of the specific downstream variable ligation 
probe of interest divided by the net concentration of all species of downstream 
Figure 31: Ligation of probe oligonucleotide is facilitated by hybridization to HBV 




variable probes. This is simply the probability that a specific species of ligation 
product has been formed, given that a ligation event has occurred. This is 
predicated on the assumption that the binding kinetics for all downstream 
variable probe sequences to the target sequence is equivalent. In principle, the 
proportion of ligation product species formed can be easily biased from one 
product to the other be adjusting the ratio of concentrations of each downstream 
variable probe. In this instantiation of the SQLA process however, I have elected 
to hold the concentrations of both downstream variable probes equal in order to 
generate two populations of ligation products of roughly equal concentration. 
Importantly, the concentration of ligation products will be proportional to the input 
concentration of input HBV DNA; in effectively splitting the input measurand 
sequence in half. The second term, 𝛼𝑙𝑖𝑔𝑎𝑡𝑖𝑜𝑛, describes the ligation efficiency 
which is defined as the fraction of input ligation template DNA sequences which 
are utilized as hybridization template and generate a ligation product. This 
assumes that any one input measurand sequence participates in no more than 
one ligation event during the reaction. The third term is the input concentration of 
ligation template which is ultimately what is to be measured by the assay. If 
100% ligation efficiency is achieved and two species of downstream variable 
ligation probes are supplied in equal concentration, then the expected 






Ligation products serve as template for isothermal amplification 
Following the formation products during the ligation phase of the SQLA 
procedure, ligation products serve as template for NAA (figure 32). Formed 
ligation products have 4 functional domains which have roles in the amplification 
procedure and subsequent detection by LFIA. The 5’ and 3’ ends of ligation 
products serve as primer hybridization sites in the antisense and sense 
orientations respectively. Because both ligation products contain the same 
upstream ligation probe sequence, amplification of either ligation product relies 
on a shared common probe. Each species of ligation product is also contains a 
primer binding domain for a unique primer at the 3’ end. In principle any NAA 
chemistry can be used for amplification provided that it can achieve amplification 
using two only primers; thus methods such as PCR, tHDA, SDA, and RPA are 
suitable, but methods such as LAMP are not. I have elected to use isothermal 
tHDA for this initial version of the SQLA assay. 
Figure 32: Ligation products contain primer hybridization domains in addition to 




If the amplification reaction is performed with an excess of unique variable 
primers relative to the common primer, then the formation of ssDNA tHDA 
amplicons can be achieved. These ssDNA amplicons can then hybridize to 
hapten-labeled probe oligonucleotides for subsequent visualization via LFIA. 
Both species of ssDNA tHDA amplicons contain the target HBV measurand 
sequence and this serves as a binding sequence for a common biotinylated 
probe oligo. Each species also contains a unique probe hybridization domain 
which can hybridize specifically to a unique probe sequence labeled with FAM or 
DIG for independent detection on anti-FAM and anti-DIG test lines contained on 
the LFIA device. 
 
Competitive amplification enables tunable detection threshold setting for 
Following the ligation step, ligation products are present at a concentration 
that is proportional to the concentration of input HBV DNA which is to be 
measured. During tHDA amplification, competition for each of the 2 variable 
primers is used to establish quantitative detection thresholds (figure 33).  
Each of the 2 ligation products has a corresponding competitive amplification 
template which is supplied to the assay at a known concentration. Each 
competitive amplification template contains a binding sequence for one of the 2 
the variable primers in addition to a unique primer. The competitive amplification 
product contains an internal sequence which does not contain hybridization sites 





competition, the formation (or lack thereof) of LFIA detectible amplicons arising 
from ligation product template is dependent on the relative concentrations of the 
ligation product which is to be measured and the known concentration of 
competitive amplification template. If ligation product is present at a high 
concentration relative to its competitive template, indicating a relatively high 
concentration of input HBV DNA, LFIA detectible ssDNA tHDA amplicons are 
formed. Alternatively, if the input HBV DNA concentration and corresponding 
ligation product concentration is low, the competitive amplicon is dominant and 
no LFIA signal is expected. By increasing or decreasing the concentration of 
competitive amplification template the detection threshold for the corresponding 
ligation product can be increased or decreased. 
Figure 33: Inclusion of competitive amplification templates are used to set tunable 
quantification thresholds in the assay. If input HBV DNA concentration is high relative 
to the amount of competitive amplification template, LFIA detectible ssDNA 
amplicons are formed. If input HBV DNA concentration is low relative to its 
competitive template, excess variable primer is diverted from the formation of LFIA 




4.3 Materials and Methods 
Oligonucleotides used in this study 
All oligonucleotides used in the development of the SQLA assay were 
purchased from Integrated DNA Technologies (Coralville, IA). Finalized primer, 
probe and template sequences can be found in table 9. All hapten modified 
probes were purified using HPLC, all other oligonucleotides (including 5’ 
phosphorylated downstream ligation probes) were purified using standard 
desalting method. FAM and DIG competitive template sequences were 
purchased as dsDNA gBlock® fragments from IDT. All ligation probe and ligation 
template oligos were diluted to a concentration of 1 µM in buffer EB and frozen 
as single use aliquots, with further dilution performed as needed after thawing. 
gBlock competitive amplification templates were diluted to a concentration of 
10^9 copies per µL in EB along with 50 ng per µL of a carrier poly-A RNA 
(Qiagen, catalog no. 1017647) to prevent adsorption of the relatively low copy 
number template DNA onto the walls of the storage tube117. Primer and hapten 
probe oligonucleotides were stored frozen as a 16X stock in single use aliquots. 
1X primer and probe concentrations for the SQLA tHDA reaction are as follows: 
common primer [85 nM], variable primer DIG [95 nM], competitive primer DIG [95 
nM], variable primer FAM [95 nM], competitive primer FAM [65 nM], common 







Ligation reactions were conducted using both T4 and T7 ligase, though 
ultimately T7 was selected for SQLA assay development. Ligases were 
purchased from New England Biolabs (Ipswich, MA) along with their supplied 
reaction buffers. Under examined assay conditions, both T4 and T7 ligase 
exhibited acceptable performance in 1X T4 buffer (50 mM Tris-HCl, 10 mM 
MgCl2, 1 mM dATP, 10 mM DTT, pH 7.54 @ 25°C), which obviated 
 
Primers   
 Common Primer 5'-TTTCCAGCGTGAAAGTAGCAGGCGTA-3' 
 Variable Primer DIG 5'-TCATGCAATGTTTTATTTCTGTGCCGT-3' 
 Competitive Primer DIG 5'-CTCATAATTAGCAAGCTGCCTCAG-3' 
 Variable Primer FAM 5'-GGTCTTACCCTCAGTTCGCAAAGGC-3' 
 Competitive Primer FAM 5'-ACTTCTGGAGCATATTGGTATCCGACA-3' 
Hapten Probes   
 Common Biotin Probe 5'-TGTTCCCCAAC/3BioTEG/-3' 
 DIG Probe 5'-CCTCTCTCTCTC/3DiG_N/- 3' 
 FAM Probe 5'-CACACACACAC/36-FAM/-3' 
Template Oligo   
 HBV Pol Template 
 
DIG Competitive Template* 
 
 










Ligation Probes   
 Common Upstream Probe 5'-TTTCCAGCGTGAAAGTAGCAGGCGTATGTGGCAATGTTC-3' 
 Downstream Probe DIG 98 5'-/5PHOS/CCCAACTTCCAATCAAAAAACCTCTCTCTCTCACGGC
ACAGAAATAAAACATTGCATGA-3' 
 Downstream Probe FAM 88 5'-/5PHOS/CCCAACTTCCAATtCACACACACACGCCTTTGCGAAC
TGAGGGTAAGACC3' 




complications that arose from presence of polyethylene glycol (PEG 6000) used 
in the recommended buffer for T7 DNA ligase during subsequent tHDA 
reactions69. Ligase was diluted to appropriate concentrations using 1X storage 
buffer (10 mM Tris-HCl, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 50% glycerol, pH 
7.4 @ 25°C) prepared in house. 
 Ligation reactions were prepared in 1X T4 DNA ligase buffer; the upstream 
common probe was added to a final concentration of 1 nM while both 
downstream ligation probes were present at 0.1 nM each. Following the addition 
of ligation template to the reaction, samples were incubated at 95°C for 1 minute 
and allowed to cool to RT to promote formation of ligatable nicks. After a 10 
minute RT hold, T7 DNA ligase at 0.3 units per µL final was added to the reaction 
and mixed by pipetting. Ligation reactions were incubated at 25°C for 15 minutes 
and subsequently held at 4°C to halt the ligation reaction. Either 2.5 or 5 µL of 
ligation product were then used as template in subsequent 25 µL PCR and 12.5 
µL tHDA reactions respectively. 
PCR of SQLA ligation products 
25 µL PCR reactions containing 5 µL of ligation product sample were prepared 
with 0.625 units of SureStart Taq polymerase (Agilent), 4 mM MgCl2, 800µM 
dNTPs, 100 nM each primer, 250 nM EvaGreen (Biotium, Hayward, CA), 1.5 nM 
ROX passive reference dye, and 1X manufacturer-supplied buffer. MgCl2 




template in T4 DNA ligase buffer, which constitutes 2 mM of the final 4 mM 
concentration. In most instances, only two primers were used for PCR 
amplification of ligation products, namely the common primer and the appropriate 
variable primer. In experiments in which both ligation products where to be 
amplified, both variable primers were included in the reaction. Reactions were 
heated to 95°C for 10 minutes to activate the hot start polymerase. 40 PCR 
cycles were performed, each consisting of 95°C for 15 s, 67°C for 30 s, and 72°C 
for 60 s with fluorescence data collected each cycle. In some instances, a 
melting curve was generated by heating samples from 72°C to 95°C to ensure 
specificity of the PCR product. 
tHDA of SQLA ligation products 
 Over the course of this work, a number of tHDA run parameters were adjusted  
to mitigate specific failure modes (e.g. primer dimer formation) and to regulate 
amplification efficiency of individual amplicons. Although further optimization of 
tHDA parameters could certainly be performed, the following parameters were 
used for SQLA assay tuning and characterization experiments and provided 
robust and repeatable assay performance. As before, IsoAmp®III tHDA kits, 
which are provided with proprietary 1X annealing buffer II and IsoAmp® dNTP 
solution (which contains excess dATP), were purchased from Quidel Corporation 
(Beverly, MA). 1X SQLA tHDA mastermix, prepared in 12.5 µL reactions, 
consists of the following reagents: 1X Annealing buffer II, 35 mM NaCl, 0.2X 




section), 2.5% Ficoll 400, 0.875 µL of IsoAmp® dNTP solution, 7.2 mM 
supplemental dATP, 9 mM MgSO4, 2 mM MgCl2, 10 mM Tris-HCl, 2 mM DTT, ET 
SSB [4ng/µL] and 1 µL of IsoAmp® III enzyme mix. Both ET SSB and IsoAmp®III 
enzyme mix were added to the mastermix just before amplification to minimize 
primer-dimer artifact formation. 1X tHDA mastermix contains 0.2X final T4 DNA 
Ligase buffer (NEB) which is reflected in the above formulation. 
 Following ligation procedures, tHDA mastermix was pipetted onto aliquots of 
ligation product (2.5 µL per technical replicate), alongside competitive 
amplification template where appropriate, mixed by vortexing and then aliquoted 
in to appropriate wells of a PCR plate prior to conducting real-time on a 
Quantstudio 5 Real-Time PCR System (Applied Biosystems, Foster City, CA) 
tHDA for 30 minutes at a constant 65°C. Following amplification, tHDA amplicons 
were examined using 10% PAGE (see chapter 2 methods) and LFIA (see below). 
LFIA readout 
SQLA amplification product was run on commercial LFIAs (D003-05, USTAR 
Biotechnologies, Hangzhou, China) which contain anti-FAM and anti-DIG test 
lines in addition to an anti-streptavidin control line. 4 µL of tHDA product is 
applied to the LFIA and 2 drops of running buffer are applied to drive wicking flow 
through the LFIA strip. The biotin-tagged tHDA products bind to streptavidin-
coated gold nanoparticles and then pass over anti-FAM and anti-DIG antibody 




nanoparticles are then captured on an anti-streptavidin antibody control line. 
LFIA strips were imaged (DS-Ri2, Nikon, Minato, Tokyo, Japan) and test line 
intensities were measured using ImageJ (NIH, Bethesda, MD); FAM and DIG test 
lines were considered positive if the measured band intensity exceeded 10% of 
the control line intensity. 
Statistical analysis 
To characterize SQLA assay tunings, serially diluted ligation template was 
used as input into the SQLA reaction and resulting LFIA test lines were labeled 
positive or negative per the section above. Using these labels, probit regression 
analysis was preformed using MATLAB to assess the probability of positive 
detection at the DIG and FAM lines as a function of input DNA template copy 
number. For both SQLA assay tuning and characterization experiments, 3 
technical replicates were performed on 3 separate days for 9 total measurements 
at each tested template condition. 
4.4 Results and Discussion 
Design rules and considerations for the SQLA assay 
The development process of the SQLA assay relied on incremental alterations 
to various reaction parameters including reagent concentrations, primer and 
probe sequences, inclusion of additives to overcome various failure modes and 
achieve consistent results. Some of the encountered failure modes appear to be 




amplification artifact generation due to specific primer sequences used) while 
others informed more generalized design principles for this assay. 
The vast majority of the encountered failure modes arose during the 
amplification stage of the assay rather than the ligation stage. Assay design 
strategies that appeared promising during early experiments tested using 
discrete, cycle-based amplification of PCR were found to be ill suited to 
translation to the desired tHDA chemistry where amplification occurs 
continuously. Because the assay is predicated on competitive amplification 
occurring in real time, identifying and controlling assay parameters which 
influence the relative amplification efficiency of each amplicon was unsurprising 
found to be of the utmost importance. 
Ligation and amplification are designed to occur in two distinct phases at 
two separate temperatures 
At the outset of this work, my goal was to develop an assay chemistry that 
would enable probe ligation and subsequent amplification from a single 
mastermix. While I believe that this is possible, a two-step reaction was instead 
implemented here for ease during the development of this proof-of-concept 
SQLA assay. This ligation followed by amplification workflow bypassed two main 
issues. The first, is that the ligation reaction and tHDA reactions differ in optimal 
concentrations of Mg2+ with ligation reactions occurring optimally at 10 mM and 




amplification technique, tHDA, does not currently exist as in a so called hot start 
formulation, thus the polymerase used in the tHDA reaction would in all likelihood 
participate in amplification artifact generation59. 
Although the resulting assay process is not truly isothermal, it can be 
accomplished with an initial ligation step occurring at room temperature and an 
amplification step at a fixed temperature of 65°C thus necessitating only a single 
controlled heat source. 
Ligation probe hybridization domain length 
The SQLA procedure relies on a mesophilic ligase (namely, T7 DNA ligase) 
which has optimal activity at 25°C followed by isothermal amplification with tHDA 
at 65°C. Ideally, ligation probe oligos should hybridize efficiently to their 
complementary sequence contained in the target genome at 25°C but avoid 
participation in subsequent amplification reactions which occurs at 65°C in the 
case of tHDA. As such, ligation probe melting temperature (TM) should fall 
somewhere between 25°C and 65°C; this can be controlled easily by modulating 
the length (in bases) of the hybridization domain of the upstream and 
downstream ligation probes. To examine the effects of altering ligation probe 
hybridization domain length, and by extension ligation probe TM, I performed 
ligation with truncated upstream probe oligonucleotides with hybridization 
domains ranging from 8 – 23 bases in length, alongside a phosphorylated 




alterations in qPCR CT values (figure 34). This study was performed using a DNA 
ligation template oligo containing a sequence within the HIV gag gene. All 
reactions were conducted with 10^7 copies of ligation template; ligase positive 
and negative reactions were included for each examined probe length to 
examine effects of hybridization domain length on ligation efficiency and 
unwanted primer activity respectively. Estimated Tm values for each truncated 
ligation probe were calculated using the OligoAnalyzer (Integrated DNA 
Figure 34: Length of the ligation probe hybridization domain had a notable impact on 
ligation efficiency and undesired primer activity. A) Hybridization domain length of the 
upstream probe was varied from 23 – 8 bases with a fixed ligation nick. B) PCR 
threshold cycle as a function of hybridization domain length C) PCR threshold cycle 






Technologies, Coralville IA) with parameters specified to the ligation conditions 
used (0.001 µM oligo concentration, 10 mM Mg2+, 1 mM dATP, 0 mM Na+). 
In the absence of ligase, a decrease in qPCR CT values was observed in 
reactions with ligation probe hybridization domain lengths of 17 bases and 
greater corresponding to predicted TM values of 52°C and above. This is 
consistent with ligation probes participating in undesired primer activity which is 
expected as the probe TM approaches the PCR annealing temperature (67°C 
was used for this experiment, tHDA occurs continuously at 65°C). In general, CT 
values for reactions where ligase was included fell between cycles 18 and 20, 
though a drop off was noted for short sequences (8 and 9 bases) both of which 
had predicted TM values lower than the ligation reaction temperature of 25°C. 
Although greater characterization is required, this finding suggests that, 
beyond a certain point, the inclusion of additional complementary bases within 
the hybridization domains of the up and downstream ligation probes distal to the 
ligation nick junction will not contribute to enhanced assay specificity. In this 
example, only the formation of hydrogen bonds between approximately 10 base 
pairs proximal to the ligation nick are required for optimal performance (inclusion 
of up to 13 additional bases did not result in a significant decrease in CT). If this is 
assumed to be the case for the downstream probe as well, then the SQLA 
measurand sequence, under the conditions examined is limited to detection of a 




specificity) could in principle be increased by any alteration that destabilizes DNA 
double helix formation including but not limited to increases in reaction 
temperature, decreases in divalent cation concentration, and inclusion of 
destabilizing reagents such as betaine. Although specificity of the SQLA reaction 
is expected to be far lower than a comparable PCR assay, it is important to 
consider the context in which this assay is to be employed. First, this test is 
intended for serial monitoring of patients with diagnosed chronic HBV infection, 
rather than for use as a first line diagnostic test. Second, the input sample for this 
assay is assumed to be processed blood or plasma, thus the presence of 
commensal organisms is not expected. For any assay to be used in this specific 
context, selectivity for HBV and not human derived nucleic acids should be 
considered an absolute minimum requirement for specificity. 
Selection of primer sequences 
The SQLA assay requires five primers (the common primer, variable primer 1, 
variable primer 2, competitive primer 1 and competitive primer 2) which can 
result in the formation of four distinct amplicons. A key advantage to the 
development of an SQLA assay is that the primer sequences are intrinsically 
orthogonal to the target genome; any set of sequences can be used in principle 
so long as they function as tHDA primers and do not generate artifacts when 
present together in a mastermix. At the outset of this work, I utilized the 4 primers 
included in the CT/TV duplex assay developed in chapter 2 plus the reverse 




Horst et al.48. These primer sequences were selected for development of this 
proof of concept assay because they were already known to be cross compatible 
(i.e. did not readily display artifact formation during amplification) and, obviously, 
functioned as tHDA primers. Over the course of this work I found that different 
primer sequences seem to respond differently to alterations in reaction 
conditions, specifically related to inclusion of extreme thermophilic single 
stranded DNA binding protein (ET SSB) and to alterations in their concentrations. 
Additionally, I encountered recurrent formation of amplification artifacts which 
required the replacement of several primers. 
Considerations regarding tHDA efficiency of SQLA amplicons 
A basic requirement that I had taken for granted initially was that all SQLA 
amplicons needed to amplify with roughly equivalent efficiencies; this is true for 
two primary reasons. First, were one of the two ligation products to amplify far 
more efficiently than the other, then that product would consume the vast 
majority of the common primer which would then in turn inhibit amplification of 
the second ligation product. The contribution of amplification efficiency from the 
common primer is shared between both ligation products, thus differences in 
tHDA efficiency between the ligation products arise largely from differences in 
performance of their respective variable primers. 
Second, if the difference in tHDA efficiency between ligation products and their 




set thresholds becomes challenging. If, for example, a competitive amplification 
product exhibited far higher tHDA efficiently than its respective ligation product, 
potential sensitivity of the assay would be decreased because relatively high 
concentrations of ligation product would be required to overcome competition 
from relatively low concentrations of competitor.  
In order to generate ssDNA tHDA amplicons from the two ligation products 
(ssDNA being required for hapten probe hybridization) it is necessary to maintain 
a higher concentration of variable primers than common primer. If, for example, 
the common primer was held at a concentration greater than or equal to the net 
concentration of the variable primers only dsDNA amplicons or ssDNA amplicons 
in the incorrect sense to hybridize to their corresponding hapten probes. Thus, 
this concentration asymmetry between the common and variable primers 
prevents a false negative LFIA readout. As I will discuss below, certain 
asymmetries in primer concentration are required for successful LFIA readout. 
This constraint is complicated by the fact that tHDA efficiency for a given product 
is influenced by the concentration of its primers, with higher primer 
concentrations resulting in more rapid amplification69. Fortunately, amplification 
efficiencies for specific primer sequences was found to vary considerably across 
the sequences tested in the assay. For example, during some of the early stages 
of assay development, the primer sequence that now serves as the common 
primer was used as the competitive FAM primer and vice versa; in this design, 




approximately 35 – 40 minutes (figure 35). By replacing the original inefficient 
common primer for a more efficient primer (“New”) threshold times were halved. 
 
Reduction of ligase concentration was found to decrease assay noise floor 
while retaining consistent templated product formation 
In 2005, it was first reported that the mesophilic T4 DNA ligase displayed 
some degree of template-independent ligation of oligonucleotides118. This 
discovery was made whilst the authors were developing a rolling-circle 
amplification assay in which the covalent closure of a circular oligonucleotide in 
the presence of a target ligation template is the first amplification step. While this 
untemplated ligation activity has little to no impact on standard ligase applications 
(e.g., cloning), this off-target enzymatic activity effectively imposes a noise-floor 
Figure 35: Substitution of an inefficient common primer sequence for a more efficient 




on assays where ligation is used for generate amplifiable template. 
In addition to testing T4 DNA ligase, which is widely used in molecular biology 
applications, I also examined the use of T7 DNA ligase, which is known to 
display only limited ligase activity on blunt ended DNA substrates relative to T4 
DNA ligase119. Reasoning that I may be able to reduce off-target template 
independent amplification through the dilution of ligase I elected to examine the 
activity of serially diluted T4 and T7 DNA ligase in the presence of 1 pM ligation 
template (figure 36). I observed that T7 DNA ligase exhibits strikingly consistent 
activity across a broad range of dilutions from stock with no indication of 
inhibition when present at high concentrations. By comparison, T4 DNA ligase 
matches this performance at 1/100X dilution but otherwise exhibits apparent 
inhibition at high concentrations and diminished activity at lower concentrations. 
I next wanted to examine the effects of ligase dilution not just in instances in 
which ligation template is present, but also in the absence of template to see if 




dilution of ligase would reduce template independent ligase activity which 
contributes to the noise floor of the assay. I observed that indeed, dilution of T7 
DNA ligase concentration was able to decrease instances of template 
independent ligation while maintaining desired activity in the presence of ligation 
template (figure 37). Ultimately T7 DNA ligase was used at a 1/10,000X dilution. 
Increased dATP and Mg2+ concentrations improved assay performance 
The SQLA assay is predicated on competitive amplification between ligation 
products and their respective competitive amplification templates. By design, the 
variable primers (one corresponding to each ligation product and competitor pair) 
are intended to be the limiting reagent in the assay. Over the course of 
development, I encountered to recurring issues that were found to have the same 
root cause (figure 38). The first issue was simply that samples with low ligation 
template load displayed progressively decreasing amplicon yield, which is 
Figure 37: Dilution of T7 DNA ligase reduces assay noise floor (template 




unexpected for a chain reaction such as tHDA which should proceed uniformly to 
a primer limited state if template is present at a detectible level. The second 
issue was that competitive amplification was found to be nonspecific; that is to 
say that inclusion of a competitive amplification template resulted in unintended 
silencing of tHDA amplicons with which they did not share a primer sequence. 
Both issues were consistent with a non-primer reagent acting as the limiting 
reagent for the assay. Assuming that tHDA enzyme stability was not an issue, 
the only other possible explanation was consumption of dATP (and to a lesser 
Figure 38: Two SQLA assay failure modes related to insufficient dATP. At low 
template loads, formation of ligation product derived amplicons was inhibited as 
evidenced by PAGE results (A) and raw fluorescence data from real-time tHDA (B). 
In a related failure mode, inclusion of a competitive amplification template should, 
under primer limited settings, cause the specific inhibition of only the ligation product 
with which is shares a primer, if a non-primer reagent is limiting the reaction, then 
this inhibition may be nonspecific; schematic view (C), PAGE results indicating that a 






extent dNTPs) which functions as an energy source for the Tet UvrD helicase 
used in the tHDA reaction56. It is known that dNTPs, as well as inorganic 
pyrophosphate which is formed as dNTPs are consumed, readily chelate Mg2+ 
and thus some recommend that, when optimizing PCR, Mg2+ and dNTP 
concentrations should be adjusted in a 1:1 stoichiometric ratio120. I observed that 
increasing dATP concentration in tandem with Mg2+ concentration enabled 
reliable amplification via tHDA of resulting from as little as 10^3 copies of 
amplification template (figure 39). 
The commercial tHDA reaction includes an unspecified concentration of dATP, 
though from early publications I expect that this is present at roughly 3 mM10,56. 
Addition of as little as 1 mM supplemental dATP allowed for amplification of both 
ligation products when 10^3 copies of ligation template was used. As expected, 
Figure 39: Increasing dATP and Mg2+ enabled consistent amplification of products 
arising from template at low (1000 copies per reaction) concentration. Interestingly, 
tHDA threshold times were consistent across conditions where the concentration of 




concentrations of dATP and Mg2+ exhibited some interplay. tHDA threshold times 
for fixed dATP and template concentrations were observed to decrease as Mg2+ 
concentration increased, while the opposite effect was observed when dATP 
concentration was increased relative to Mg2+. Threshold times were consistent 
across conditions when the difference between Mg2+ and dATP concentration 
was held consistent. While higher Mg2+ concentrations did considerably reduce 
threshold amplification times, they also seemed to lead to a reduced robustness 
of amplification with faint products observed by PAGE. 
Increasing dATP and Mg2+ concentration was also found to restore specific 
competition between competitive templates and their respective ligation products 
(figure 40). When only 1 mM of supplement dATP was utilized, inclusion of 10^6 
copies of competitor (targeting the lower molecular weight, 88 bp ligation 
product) resulted in inhibition of both ligation products. As dATP concentration 
was increased (alongside Mg2+ concentration) silencing of only the 88 bp ligation 




This simple strategy of increasing dATP concentration concurrently with Mg2+ 
concentration should have broad applicability in multiplex NAATs which are 
reliant on nucleotide/nucleoside triphosphates as an energy source including 
tHDA and recombinase polymerase amplification (RPA). In chapter 2, I examined 
strategies for multiplexing CT and NG tHDA assays, and tested a case where CT 
and NG templates were present at differing concentrations (figure 11). I observed 
that when CT template was present at a concentration 100 fold greater than NG 
template, formation of the NG amplicon was inhibited at high primer 
concentrations. Although not tested, it is likely that simply increasing dATP 
concentration could have resolved this issue. 
  
Figure 40: Increasing dATP and Mg2+ concentrations restores specificity to 
competitive amplification of ligation products and their competitive templates. In this 
case 10^4 copies of ligation template are present in all reactions. Formation of the 
competitive amplification product should inhibit formation of only the lower molecular 




Tuning FAM and DIG LFIA quantification thresholds 
Although the process of primer and probe design and identification of optimal 
run parameters for the SQLA assay is somewhat more complicated than for a 
comparable NAAT, the process of quantitative threshold setting or assay tuning 
is relatively straight forward. To demonstrate the tunability of the SQLA assay, I 
decided to generate and characterize two distinct tunings with differing 
quantification threshold for the DIG and FAM test lines. Given that useful 
quantification thresholds for treatment management of chronic HBV infection 
were identified by the AASLD at 2,000, 20,000 and 200,000 IU/mL (10^4, 10^5 
and 10^6 HBV DNA copies per mL) I wanted to develop a tuning with a 1 log 
difference in thresholds (10^4 and 10^5 copies) as well as a 2 log difference in 
thresholds (10^4 and 10^6 copies). In practice, specific correspondence between 
the copy number based thresholds examined here and the concentration based 
thresholds used for clinical decision making is in principle dependent on the 
upstream sample preparation workflow to be used as input volume, extraction 
efficiency, and nucleic acid enrichment all need to be taken into account. 
As before, biotinylated analytes contained in the sample applied to the LFIA 
devices first hybridize to streptavidin coated gold nanoparticles (AuNPs) before 
moving past anti-FAM, anti-DIG, and anti-streptavidin test and control lines in 
that order. In this multiplexed format, it is possible for individual AuNPs to 
hybridize to amplicons that contain both FAM and DIG moieties. AuNPs coated 




due to the fact that this test line is encountered first. From a design perspective, 
selection of the FAM test line for the high quantitative threshold made the most 
sense as the high quantitative threshold contains more information that the low 
quantitative threshold (e.g. if a given sample had enough ligation template to 
produce a positive result a FAM threshold set to 10^6 copies, it should also 
contain enough template to exceed a DIG threshold at 10^4 copies). 
To tune specific thresholds, the concentration of ligation template is held 
constant at the desired threshold concentrations (in this case 10^5 and 10^6 
copies) and the amount of competitive amplification template for the given test 
line (in this case FAM) is titrated. The expected result is a diminished anti-FAM 
test line as the amount of the appropriate competitive amplification template is 
increased. Results were found to be in line with this expectation (figure 41). As 
the amount of competitor was increased, a clear decrease in the anti-FAM test 
Figure 41: Sample LFIA strips with increasing FAM competitor (A) and formula for 




line signal is noted. For context however, the goal of this project is to achieve an 
non-instrumented, naked-eye readout in which the presence or absence of a 
given test line is used to achieve a semiquantitative measurement of the input 
template. Intrinsic to this goal is the assumption that the presence or absence of 
a test line is an easily measured binary variable. In reality, test line band intensity 
is a quantitative output from the LFIA device to which a user assigns a label, 
either positive or negative. Faint test lines therefore present a challenge to this 
assumption. To avoid subjective judgment calls, FAM and DIG test line signals 
were quantified using densitometry analysis on ImageJ and normalized across 
LFIA devices by comparison to their respective control line signal. For the 
purposes of this work, I attempted to tune LFIA test lines such that 10% of control 
line signal was present at my desired threshold. Taken in aggregate and using 
this 10% control line cut off to select a concentration of competitor, I found that a 
10^6 quantitative threshold could be established used 10^5 copies of competitor 
and that at 10^5 quantitative threshold could be established using 10^4 copies of 




This tuning process was repeated for the DIG line which was to be tuned to 
10^4 copies of ligation template in both cases. I observed that 2.14*10^2 copies 
of DIG specific competitive amplification template was sufficient to set a 
quantification threshold at this concentration both when 10^4 and 10^5 copies of 
the FAM specific competitive amplification template were included (figure 43). 
Through this simple process I was able to establish pairs of tuned LFIA 
quantification thresholds. Using these two tunings, I next characterized LFIA test 
line intensities in response to variate in input ligation template concentrations.  
 
Figure 42: FAM line quantification threshold tuning. At fixed concentrations of 
ligation template, normalized anti-FAM test line signal diminishes as competitive 
amplification template copy number is increased. Assuming that samples where 
normalized FAM signal exceeds 0.1 are considered positive and lower are 
considered negative, inclusion of 10^5 copies of competitor established a 
quantification threshold at 10^6 copies of HBV ligation template (A) while 10^4 






Analytical characterization of 2 SQLA assay tunings 
After identification of appropriate competitive amplification templates to 
establish two distinct assay tunings, these tunings were tested by performing the 
assay with serially diluted HBV pol ligation template oligo (Figures 44 & 45).  
In both assay tunings, a shift in SQLA amplicon distribution can be observed 
as the amount of ligation template is decreased from either 10^7 or 10^6 starting 
copies down to 10^3. At high ligation template concentrations, both the 98 bp 
DIG specific ligation product amplicon and the 88 bp FAM specific amplicon 
appear as dark bands on PAGE. As the ligation template concentration 
decreases, the 72 bp FAM and 80 bp DIG competitive products increase in 
intensity while the corresponding anti-FAM LFIA test lines diminish in intensity. 
Figure 43: DIG line quantification threshold tuning. At a fixed concentration of 
ligation template (10^4 copies per reaction) increasing amounts of DIG specific 
competitive amplification template results in diminished anti-DIG LFIA test line signal. 
2.14e2 copies of the competitive plasmid established a quantification threshold at 
10^4 copies of input HBV ligation template both when 10^4 (A) and 10^5 (B) copies 






Figure 44: SQLA assay tuning targeting FAM threshold at 1e6 copies and DIG 
threshold at 1e4 copies. (A) Sample PAGE results and (B) corresponding LFIA strips 
demonstrate a change in SLQA amplicon production as a function of input HBV 
control oligo concentration. (C) Normalized DIG and FAM LFIA test line signals. (D) 
Probit analysis of FAM and DIG lines as a function of HBV DNA concentration with a 
10% normalized LFIA test line signal used as a threshold to classify positive and 









Figure 45: SQLA assay tuning targeting FAM threshold at 1e5 copies and DIG 
threshold at 1e4 copies. (A) Sample PAGE results and (B) corresponding LFIA 
strips demonstrate a change in SLQA amplicon production as a function of input 
HBV control oligo concentration. (C) Normalized DIG and FAM LFIA test line 
signals. (D) Probit analysis of FAM and DIG lines as a function of HBV DNA 
concentration with a 10% normalized LFIA test line signal used as a threshold to 








 I note that absence of AuNP aggregation on LFIA test lines does not strictly 
correlate with presence or absence of the corresponding ligation template 
derived amplicons on PAGE, but rather correlates more strongly with presence of 
the competitive amplification product. This is consistent with the expectation that 
LFIA detectible amplicons are ssDNA products, which are not visible by SYBR 
green staining, rather than the dsDNA products observed via PAGE. 
 With respect to accuracy of the SQLA assay and tuning process, apparent 
assay thresholds occur roughly at the expected concentrations. Binary detection 
in the DIG and FAM test lines was observed at 10^4 and 10^6 copies of input 
template for in the first tuning (figure 44d) and 10^5 and 10^3.67 for the second 
tuning (figure 45d). The input ligation template concentrations corresponding to 
observed  binary detection events matched the intended quantification threshold 
concentrations with the exception of the FAM test line in the second tuning which 
fell slightly lower than the intended 10^4 copy quantification threshold. 
An ideal threshold-based detection assay would result in positive detection for 
all measurand input concentrations exceeding the threshold concentration and a 
negative result for all lower concentrations. In practice, probability of a positive 
detection event can be modeled using regression, in this case probit analysis 
proved useful. The probit model fit for each of the test line was used to determine 
input concentrations of ligation template predicted to result in 5% and 95% 
positivity (C5 and C95). For all for thresholds tested, probit C5 and C95 




quantification threshold suggesting that the range of concentrations with 
ambiguous results is fairly narrow. 
4.5 Conclusions 
 In this work, I presented a proof-of-concept demonstration that our SQLA 
assay is capable of generating consistent binary quantification thresholds using 
chemistries that require only room temperature and 65°C incubations. These 
quantitative thresholds have also been demonstrated to be easily tunable 
requiring only the titration of competitive amplification templates to obtain 
semiquantitative information about template DNA concentration. Results were 
found to be consistent over multiple days indicating that the SQLA procedure is 
indeed repeatable. Further testing should focus on assessing specificity of the 
SQLA process against commensal organisms and for selectivity across known 
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